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 ABSTRACT 
HIV/AIDs is a prevalent disease infecting millions of people throughout the world.  Although a 
lot of improvement has been achieved over the year in regard to the reduction of AIDs related 
deaths, a huge task lies ahead as the HIV/AIDs global epidemic keeps spreading annually.  It is 
therefore paramount to discover and develop more and efficient drug inhibitors against HIV.  
The HIV protease (HIV PR) is a C2-symmentric homodimer and consisting of 99-amino acids in 
each monomer and because of the important role it plays in the HIV mutation, it became a major 
HIV drug target for the past three decades.  It is on this basis that various effective antiretroviral 
protease inhibitors have been designed and approved for application in HIV therapy. 
The HIV subtype B strain is prominent in Europe and North America and is the most researched 
virus.  The majority of the antiretroviral drugs were designed and tested against HIV subtype B.  
However, non-subtype B strains of the HIV virus makes up most of these infections in Southern 
and Eastern Africa, which are highly affected regions in the world.  In South Africa, subtype C 
HIV-1 is the dominant strain and little research has been done regarding drug design for this 
subtype or testing of the effectiveness of the HIV approved antiretroviral drugs against these 
non-subtype B strains.  Two potentially devastating mutations of subtype C-SA HIV PR were 
recently reported by our group.  These were designated I36T↑T and L38L↑N↑L HIV PR.  The 
I36T↑T PR mutant includes an extra amino acid, the mutation occurs at position 36 (isoleucine to 
threonine) and is followed by an insertion at the second threonine indicated by the upward arrow.  
The L38L↑N↑L PR mutant involves two amino acids insertions that is completely different from 
the usual 99-amino acids HIV PR, as well as five point mutations occur at the E35D, I36G, 
N37S, M46L and D60E.  The two insertions occur at position 38 (asparagine and leucine) 
indicated by the two upward arrows.  Therefore, the I36T↑T and L38L↑N↑L mutations consist of 
100 and 101-amino acids in each monomer of the proteases respectively.  
In this thesis, a hybrid computational model (QM: MM) using the ONIOM approach was 
followed.  The selected FDA inhibitors were complexed with the various proteases in the active 
pocket interacting with Asp 25/25' catalytic residues using the same pose in the subtype B PR as 
a reference X-ray structure.  The HIV PR inhibitors and Asp 25/25' were treated at a high-level 
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with quantum mechanics (QM) theory using B3LYP/6-31G(d), and the remaining HIV PR 
residues were considered at a low layer using molecular mechanics (MM) with the AMBER 
force field.  This method was applied to calculate the binding free interaction energies of the 
selected FDA approved HIV PR drugs complexed to the HIV protease enzyme.  The aim was to 
create and test this computational model that will reflect the experimental binding energies 
against subtype B, C-SA HIV PR and also a mutant from the subtype C-SA PR designated 
L38L↑N↑L HIV PR. 
The calculated binding free interaction energies results from the subtype B follow a satisfactory 
trend with the experimental data.  However, the C-SA HIV PR inhibitor―enzyme complexes 
showed some discrepancies and this was ascribed to the simplified computational model that 
omitted water in the active site of the enzyme.  The calculated binding free interaction energies 
for L38L↑N↑L PR as well as experimental results, showed reduced binding affinities for all the 
selected FDA approved inhibitors in comparison with the subtype C-SA HIV PR.  The deviation 
could be as a result of the insertion and mutation of the subtype C HIV-1 PR that is expected to 
have a significant effect in altering either the binding affinity of the HIV PR inhibitors and or 
characteristics of the parent protease.  
The computational model used in this research will be improved by introducing water into the 
active pocket of the Asp 25/25' catalytic residues that will be treated at least at semi-empirical 
level.  Optimization of the different ONIOM levels will be attempted in order to accurately 
predict activities of new potential HIV PR inhibitors. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Preface   
Human immune deficiency virus (HIV) has been a long-standing disease since it was first 
identified in the early 80’s at the Institute Pasteur, Paris by Luc Montagnier1, 2, before it was 
further characterized by Robert Gallo and Jay Levy in 19843. This virus infects both human and 
animals and if not quickly treated/prevented, develops into a deadlier disease known as Acquired 
immune deficiency syndrome (AIDS)1, 4, 5. HIV is transmitted through different means including; 
(i) mother to child (childbirth), (ii) incision (iii) blood transfusion and (iv) sexual intercourse 
(which is the most common)6.  
According to statistics provided by the World Health Organization, HIV has claimed the lives of 
millions of people. An estimate of 36.9 million people was reported to be infected with HIV as 
of 2015, with women having the greater percentage (17.4 million) and an estimated 2 million 
new HIV infections occur globally each year. Of this, 69% people are living in sub-Sahara 
Africa, while in South Africa statistics indicate that 5.26 million people are living with HIV, 
which is an estimated 10% of the country population7.  
These figures, both worldwide and in South Africa, indicate that scientist continue to be faced 
with the challenge of finding a cure for the virus. Various research has been carried out by 
scientists all over the world with the support of the different organizations to find a lasting and 
more effective drug to totally inhibit this epidemic5, 8. This has led to the study of the HIV virus 
at large. 
Intensive study of the life cycle, structure, of the human immune deficiency virus led to the 
development of unrivaled anti-viral drugs targeting the three (3) important retroviral enzymes; 
Integrase (IN), Reverse transcriptase (RT), Proteases (PR). The combination therapy (highly 
active antiretroviral therapy HARRT) that was developed in the 1990’s is made up of a NRTI 
(Nucleoside reverse transcriptase inhibitors), NNRTI (Non-nucleoside reverse transcriptase 
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inhibitors) and PRIs (Protease inhibitors). This treatment was the first to give HIV/AIDS patients 
better prospects for the future9, 10,11. 
HIV protease inhibitors (HIV PRIs) have been found to rapidly decrease the spread of viral 
infections in tractable cells which makes this aspartate enzyme a predominant target in the 
prevention of the deadly disease known as Acquired Immune Deficiency Syndrome (AIDS)12, 13. 
Protease inhibitor drugs approved by the Food and Drug Administration (FDA) were mainly 
designed for HIV subtype B14-17. The confined data available indicate that these protease 
inhibitors show less activity against subtype A and C18. This may be due to the mutation and late 
stage maturation in HIV-PR that renders the protease inhibitors inactive18, 19. To date, only five 
of the approved FDA antiretroviral drugs are available in South Africa for the Human immune 
virus protease (HIV-1 PR C-SA)20. Therefore, it is imperative to study the potency of the 
approved FDA drugs against this strain and its mutants. 
Several computational techniques ranging from Thermodynamic integration (TI), Free energy 
perturbation (FEP), Molecular mechanics Generalized Born surface area (MM-GBSA), linear 
response (LR), Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA), are widely 
known for the investigation of binding energies of HIV protease―ligand complexes18, 21, 22. 
A great number of studies have been done using Our Own N-layered Integrated molecular 
Orbital and molecular Mechanics (ONIOM) process and it was found to be applicable to large 
molecules in different research areas23, 24. These includes; reaction mechanisms for organic 
system, determining binding interaction energies, enzyme reactions, surface reaction and cluster 
models of surfaces, and reactivity of organic and organometallic compounds25-28.   
In this study, we investigated the inhibitory activity of the current FDA drugs with respect to 
their binding affinities against subtype B, C-SA and L38L↑N↑L HIV-1 PRs using a ONIOM 
model. 
1.2 HIV Virus  
The Human immune deficiency virus belongs to the family of retrovirus (lentivirus)1,8 and can be 
categorized into two types; HIV-1, which is similar to Simian immunodeficiency virus (SIV). It 
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is the most common and found worldwide, while HIV-2, is frequent in Western and Southern 
Central Africa and also Western India4. These types of HIV can be further classified into 
subtypes, sub-subtypes and recombinant forms29, 30. Of the ten subtypes of HIV-1 virus, subtype 
C is prevalent in Africa, mostly South Africa, while subtype A is found to be common in Central 
Africa, and Australia, Western Europe, and North America majorly account for subtype B HIV 
type 118, 29-31. The major difference between the different HIV subtypes is the natural amino acids 
polymorphisms at various positions, but the mechanisms in which they operate remain the 
same32. 
The structure of the Human immune virus type 1 (Figure 1) is 100 nM in width, and the viral 
particle is enveloped with a lipid bilayer diaphragm, that cut across the uppermost layer of gp120 
(glycoprotein) and binds along gp41 (transmembrane proteins). Matrix shell protein (p17) as 
shown in figure1 forms the linear surface directly underneath the lipid bilayer membrane. The 
p24 (capsid matrix) form a cone-shaped positioning that encompasses the p7 and p9 gag 
(nucleocapsid proteins), integrase, reverse transcriptase and protease1, 33. The HIV virus genes 
comprise of two lone RNA (Ribonucleic acid) strands that are subsequently transcribed into 
DNA (Deoxy-ribonucleic acid) by viral transcriptase when it penetrates the human immune cells. 
Susceptible cells such as macrophages, dendritic cells, and CD4+ T cells are the major human 
cells the HIV virus infects34. 
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Figure 1. Diagram of HIV genome35.  
1.2.1 HIV-1 Life-cycle 
The absence of antiretroviral drugs in HIV-infected patients leads to 3 phases; the acute phase is 
the first stage and this is when the viral replication is very fast, the chronic phase (second stage), 
takes a very long time estimated at a period of 9-10 years. The last stage is full-blown AIDS, and 
in this stage, the immune system has totally lost control over the viral replication36. 
When the HIV virus enters a human cell a process begins by interacting with the host cells CD4+ 
protein and co-receptor CCRS (CC Chemokine receptor 5)37, that is recognized by a viral 
envelope gp120 (glycoprotein) or gp41 (transmembrane protein) in the immune system38 (Figure 
2). Once HIV is manifested in the T-cell, 3 enzymes; Reverse Transcriptase, Integrase 
Transcriptase, and Protease are important in the viral replication process36. 
The viral genetic material from RNA enters the cytoplasm and reverse transcribed into a single 
DNA before it is further transcribed to a double stranded deoxy-ribonucleic acid (ds DNA). 
These series of actions are subjected to an immense number of errors and leads to the emergence 
of mutations for each viral generation produced. As the double-stranded DNA viral genome 
enters the nucleus of the cell, by means of reverse integrase, becomes the host genome1, 32, 39. The 
provirus DNA is again transcribed into RNA and further transcribed into polyproteins that 
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comprise of env, gag and gag-pol precursors8, 19. Polyproteins and immature RNA virus are 
assembled into viral particles, the protease helps in cleaving the polyproteins to more functional 
protein building blocks, which is required for the mature virus36, 40-42. Each enzymatic stage can 
potentially be interfered with, thereby slowing down or stopping the replication of the virus, 
these essential enzymes are therefore potential drug targets. Zidovudine was the first successful 
synthesized drug for the treatment of cancer in 1964 but was later found to be effective against 
HIV in 1987, it was on this basis that other drugs were then designed and synthesized5. 
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Figure 2. Schematic representation of HIV Life cycle43   
1.3 HIV Inhibitors 
Inhibitors bind onto enzymes and block or inhibit their activities44. Enzymes inhibitors are 
categorized based on their mechanism of action and it can either be specific or non-specific45. 
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Specific enzyme inhibition can be further classified into irreversible and reversible inhibitors. 
While non-specific inhibition is irreversible in nature and it binds strongly to the enzyme and it is 
very unlikely to dissociate from it, only by extreme pH condition or high temperature and this 
denatures the enzyme45.  
1.3.1 Irreversible Inhibitors 
Irreversible inhibitors covalently bind with an enzyme and because of their high affinity, once 
bound they do not dissociate easily from the enzyme. They can also form a non-covalent binding 
interaction with the active site of an enzyme45.   
1.3.2 Reversible Inhibitors 
The defining properties of these inhibitors is the ease with which they non-covalently bind and 
can dissociate from the enzymes under certain conditions45-47. A discussion of reversible 
inhibitors is provided next.   
1.3.2.1 Competitive Inhibitors 
These inhibitors resemble the structure of natural substrates that bind in the active site and 
because of the similarity in structure, these inhibitor bind exactly in the same location as the 
substrates44.  Therefore, competitive inhibitors as the name implies, will compete with the 
substrate for the active site and due to higher affinity than the substrate and once bound prevents 
the substrate binding to the active site45, 47, 48. 
1.3.2.2 Uncompetitive Inhibitors 
Uncompetitive inhibitors bind in the pocket created by a change in enzyme conformation of 
substrate binding to the active site. This forms an enzyme-substrate inhibitor (ESI) complex 
which essentially blocks the activity of the enzyme45, 47.   
1.3.2.3 Non-competitive Inhibitors 
Some enzymes have a permanent allosteric site (non-substrate binding site) that is generally 
different from the active site48. This allows binding of inhibitors to the allosteric site, regardless 
of if the enzyme is free or a substrate is bound to it. These inhibitors are non-competitive because 
they do not compete for the active site with the natural substrate and thus block the enzymatic 
activity of the enzyme44, 47.   
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1.3.2.4 Mixed Inhibitors 
The inhibitor in this type of inhibition not only compete for the active site with the substrate but 
also binds unto a free enzyme molecule which further binds a substrate or binds to a substrate-
enzyme complex and reduces catalytic turnover45-47. 
1.4 Types of HIV Inhibitors   
Different inhibitors at different stages of the HIV life cycle have proved to be efficacious in 
inhibiting enzymes responsible for reproducing the catalytic activity of the virus, acting as 
potential drug targets49. 
1.4.1 Entry Inhibitors 
Entry inhibitors inhibit virus from entering and transmitting to the host cell. These inhibitors are 
broadly categorized into; co-receptor antagonist, fusion inhibitors, and attachment or binding 
inhibitors1, 38. 
1.4.1.1 Co-receptor Antagonists (CRAs) 
The T-cell consists of two co-receptor namely CCR5 and CXCR4 and this inhibits the entry of 
the HIV virus that interacts with the co-receptor50. A principal drug that targets the C-C 
chemokine receptor type 5 (CCR5) co-receptor includes monoclonal antibody and Pro140 which 
prevents HIV type1 virus by engaging the glycoprotein (gp120) binding spot on CCR551. Co-
receptor antagonist capability to block HIV infection has been displayed in animal models and 
cell culture systems. An early example of a CCR5 antagonist (Figure 3) that was approved in 
2007 is Maraviroc52, 53. 
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Figure 3. Structure of a CCR5 antagonist inhibitor54  
1.4.1.2 Fusion Inhibitors (FIs) 
Enfuvirtide was approved by the FDA in 2003 and so far is the first and only therapeutic 
administered fusion drug55, the structure is a linear chain of 36-amino acids that corresponds to 
127-162 residues of viral gp14 (Figure 4). This type of inhibitor blocks the change in formation 
of the glycoprotein (gp14) that is involved in the integration of the virus and host cell 
membrane50. 
 
 
Figure 4. Fusion inhibitor sequence56  
1.4.1.3 Binding or Attachment Inhibitors (AIs)  
Attachment inhibitors interrupt the inceptive binding of the HIV-type1 glycoprotein 120 exterior 
to the CD4 T-cell receptor by one of the various feasible mechanisms50. Figure 5 presents 
samples of clinically successful attachment drugs51, 57. 
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-
GlnGlu-Leu-Leu-Glu- Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 
Enfuvirtide (2003) 
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Figure 5. Schematic representation of binding inhibitors51 
1.4.2 Reverse Transcriptase Inhibitors 
The RTIs (that is, ‘non-nucleoside reverse transcriptase’ (NNRT) and nucleoside reverse 
transcriptase (NRT) inhibits reverse transcriptase enzymatic purpose and intercept the synthesis 
completion of the double-stranded viral DNA. Thus restrain human immune virus from 
multiplying36, 58. 
1.4.2.1 Nucleoside Reverse Transcriptase Inhibitors 
NRTIs compete with the natural deoxynucleotides substrates even though they lack the 3-
hydroxyl group on the deoxyribose moiety. Hence, the addition of NRTIs during DNA 
transcription prevents further covalent 5'-3' phosphodiester bond that is formed by the next 
incoming deoxynucleotide. Thus, resulting in viral transcription chain termination59, 60. 
Zidovudine (AZT) was the first nucleoside reverse transcriptase inhibitors (NRTIs) drug 
approved in 1987 for HIV treatment and presently, there are seven FDA approved NRTIs drugs 
in the market11. Some examples are shown in Figure 6. 
 
Figure 6. Structure of FDA approved NRTI drugs11 
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1.4.2.2 Non-nucleoside Reverse Transcriptase Inhibitors 
NNRTIs, in contrast inhibits reverse transcriptase by binding at the allosteric site (non-substrate 
binding site) specifically different from the active site. Thus, blocking the movement of protein 
domains of HIV-1 RT-DNA viral replication42, 61. The Food and Drug Administration (FDA) 
approved Five NNRTIs drugs  from 1996-201111 (Figure 7). 
 
Figure 7. Structure of FDA approved NNRTI drugs11  
1.4.3 Retroviral Integrase Inhibitors 
Integrase inhibitors belong to a class of antiretroviral drug, designed to inhibit the activity of that 
enzyme. This viral enzyme transmits the viral genome into the DNA of the host cell and since 
integration is also an important viral phase in retroviral replication, inhibiting it can prevent 
further spreading of the virus1, 36. Development of HIV-1 RIs is lagging behind owing to the fact 
that the structure of the retroviral integrase has not been fully elucidated. In 2007 the FDA 
approved Raltegravir (Figure 8) as the first integrase inhibitor62. 
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Figure 8. Schematic representation of approved FDA HIV-1 integrase inhibitor62  
1.4.4 Protease Inhibitors 
HIV protease inhibitors are peptide-like chemicals that competitively inhibits the cleavage of gag 
and gag-pol from transmitting into a functional virus30, 63, 64. The FDA approved protease 
inhibitor drugs include; Saquinavir (is the first and most widely administered drug)65, Indinavir, 
Tipranavir, Amprenavir, Nelfinavir, Lopinavir, Ritronavir and Atazanavir18, 66 (Figure 9). 
Human immune virus protease inhibitors (HIV-1 PRIs) advantages include; better viral 
suppression, prolonged viral control, reduction of death rates. These PR inhibitors have been 
reviewed intensively and they show antiviral, pharmacodynamics, pharmacokinetics (which 
includes; absorption, distribution, metabolism and excretion of drugs) properties67-69. Therefore, 
HIV treatment is worthwhile for patients infected with HIV virus32, 36. Although, some setbacks 
have been drawn from mutations and polymorphisms that occur within the protease and this has 
led to the development of combined antiretroviral therapy (cART), where HIV-1 PR is the top 
target30, 63, 70. 
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Figure 9. Structures of HIV-1 approved protease inhibitors18, 71, 72 
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1.5 HIV-1 Protease  
Human immune virus type 1 protease, belong to the family of aspartyl protease26, 29, and since it 
plays a key role in HIV virus mutations, it has become an important target for antiretroviral 
drugs64, 73. The HIV-1 PR exists as an identical active C2-symmentric homodimer with 99 amino 
acids in each dimer65, 66. The active sites consist of Asp25-Thr26-Gly27 triad at each half 
enclosed by a two beta-sheets flaps4, 30. Asp25 and 25' of the active site interact directly with the 
inhibitors and substrates, while the role of the other amino acids (Thr26, 26', Gly27, 27') is still 
largely unknown39. The nucleotide sequence of HIV-1 PR has been observed to change from 
generations due to high error rates of HIV reverse transcriptase8. However, the catalytic triad 
residues of HIV PR, Asp25-Thr26-Gly27, is well conserved and it is similar in all HIV 
subtypes29, 30, 74.The protease enzyme has three domains as shown in Figure 10 and will be 
discussed in the next section.  
 
Figure 10. Ribbon representation of HIV-1 protease75 
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1.5.1 Domains in HIV-1 PR Dimer 
(i) The core domain or active site cavity 
(ii) The terminal domain or dimerization domain and  
(iii) The flap domain   
1.5.1.1 Core Domain (active site cavity) 
The active site cavity is important in the stabilization of the dimer as well as the catalytic site. 
This domain is composed of four beta-strand structures. The catalytic tripeptide Asp25-Thr26-
Gly27 is situated at the core domain interface from the monomers8, 76, 77. 
1.5.1.2 Terminal Domain (dimerization domain) 
This domain plays a vital role in the stabilization of active site and dimer formation. The 
terminal domain is composed of β-antiparallel sheets that comprise of four termini dimer 
residues 1-4 and 95-99, the helix residues 86-94, and a turn encompassing residues 4-9 of each 
monomer78. 
1.5.1.3 Flap Domain 
The flap domain consists of two β-hairpin structures30, 43-58 amino acids residues found in both 
monomers77, 79. Studies have revealed that the HIV-1 PR exhibit structural arrangement from 
closed form, semi-open form and wide-open form, which covers the active site and this plays a 
vital role in the ligand―substrate binding interaction80, 81. Though the HIV protease has been 
crystallized as a single monomer (PDB code: 1HHP)82, it functions as a dimeric form. The dimer 
is established due to intermolecular forces contributing to its stability and it is observed in 
complexes of the HIV-1 PR with inhibitors82. 
1.5.2 Dimer Stability of HIV-1 PR 
HIV-1 PR dimer stabilization is attained by factors which include side chains hydrophobic 
interactions, non-covalent interactions, and interactions including the catalytic residues78. A 
network of hydrogen bonds referred to as “firearm” is produced by the PR catalytic residue 
‘Asp25-Thr26-Gly27’ triad80, 83 and it is depicted in (Figure 11). 
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Figure 11. Schematic representation of the catalytic residues triad Asp25-Thr26-Gly2783  
1.5.3 Substrate Binding 
The active site cavity is composed of distinct subsites, where the substrates side chains are 
accommodated upon binding. The defined subsites are named S1 to Sn and S1' to Sn' for each 
monomer and while the corresponding amino acids side chain of the substrate that is cleaved 
during hydrolysis are named P1 to Pn and P1' to Pn', starting from the scissile bond
84 (Figure 12). 
However, the protease subsites S1 and S1' are the same, as a result of the C2 symmetric nature 
and this holds for all other subsites8, 64, 85. 
 
Figure 12. P1___Pn, P1'____Pn'_is a standard nomenclature used in representing amino acids of peptide 
residues, while protease binding sites are represented by S1___Sn, S1'____ Sn'_
8, 86.  
1.5.4 HIV-1 PR Catalytic Mechanism 
Despite all that was investigated about HIV-1 PR and the importance of the protease family, the 
mechanism by which it catalysis the proteolysis of the peptide remains a formidable challenge13, 
19, 74. Experimental studies have shown several factors such as; the catalytic aspartate protonation 
state and the role of structural water, and also the identification of the Asp25-Thr26-Gly27 
catalytic triad 13, 19. Based on structural observations of different Aspartic protease complexes, 
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several distinct mechanisms have been proposed74. This falls generally into two categories: 
general Acid-Base (GA-GB) catalytic mechanism and catalysis through a covalently bonded 
intermediate13 and it is represented in Figure 13. Although there is no definitive proof yet as to 
which mechanism is right, most studies indicate a general acid-base reaction mechanism for 
peptide cleavage bond74, 87. The peptide carbon hybridization changes from sp2 to sp3 caused by a 
nucleophilic attack from water molecule at the scissile bond74, 87-90. The un-protonated ASP-PR 
which acts as the general base helps in the ionization of the water molecule and becomes 
protonated, the resulting hydroxyl ion cleaves and bond covalently with the peptide carbon, 
initiating the carbon-nitrogen (peptide) bond breakage87, 88. 
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Figure 13. General HIV-1 PR catalytic mechanisms (a) Acid-base general mechanism with water, (b) 
Acid-base reaction with a zwitterion molecule, (c) Direct nucleophilic reaction with covalently-bonded 
intermediate8, 13, 88.   
1.6 HIV-1 PR Mutations  
Over time, multiple mutations of the HIV-1 PR have developed that show resistance to the 
available anti-retroviral drugs91. The lack of proofreading of the reverse transcriptase and high 
viral replication rate contributes significantly to a build-up of drug resistance of this protease92. 
(1) 
b 
c 
(1) 
(1) 
a 
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The insertion, substitution, and deletion that occur in the amino acids of the virus sequence are 
attributed to mutations that arise through resistance31. The structure of the active site in the 
wildtype HIV PR is influenced by these mutations, which then diminishes the efficacy of the 
protease inhibitors93-97. 
The structure of subtype B differs from the subtype C-SA PR as a result of a mutation that occur 
in eight different positions away from the active pocket of the wild-type subtype B31. Likewise, 
two new mutations have been found to occur from the C-SA HIV PR designated I36T↑T and 
L38L↑N↑L PRs98. The former (I36T↑T) has a 100 amino acids in each monomer and the 
mutation occur at position 36 from isoleucine to threonine, with an insertion at the second 
residue of threonine. While, the later (L38L↑N↑L) with an insertion in the asparagine and leucine 
at position 38 has 101 amino acids in each monomer was reported98, 99.  The protease has five 
mutations E35D, N37S, I36G, D60E and M46L and was discovered in a drug-naïve patient (with 
respect to PIs)98.  
1.7 Objectives of this Study 
The primary scope of this study is to test and improve a pre-existing computational model to 
correctly reflect the experimental data in terms of binding interactions of available HIV PR 
inhibitors. This is accomplished by the following objectives;  
 To create a computational chemistry model using a ONIOM (two-layer) method to 
calculate theoretical binding free energies. These results will be compared with reported 
experimental binding energies of FDA approved HIV protease inhibitors against subtype 
B and C-SA HIV PR. 
 To test the performance of the same ONIOM computational model for the C-SA HIV PR 
mutant designated L38L↑N↑L PR. The theoretical binding free energies will be compared 
with our recently reported experimental binding energies of the FDA approved PR drugs 
to this mutant.   
1.8 Thesis Outline 
This dissertation continues as follows: 
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A computational study background is presented in Chapter 2. 
ONIOM theoretical model to calculate the binding interactions and reflect the experimental 
binding energies of FDA approved HIV-1 PR inhibitors against subtype B and C-SA PR is the 
focus in Chapter 3. 
The tested computational chemistry model (ONIOM) in investigating the binding interactions 
and also reflect experimental binding energies of PR inhibitors against C-SA HIV PR mutant 
L38L↑N↑L PR is discussed in Chapter 4. 
Summary of the dissertation is followed in Chapter 5. 
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CHAPTER TWO 
 COMPUTATIONAL BACKGROUND 
2.1 Introduction to Computational Techniques 
Theoretical structural calculations was first introduced in chemistry by Walter Heitler and Fritz 
London in 19271, and ever since, there has been an outstanding progress and dynamic use of 
computational techniques in research.  An intensive background on molecular modelling is 
readily available in literature2-6.  The combination of molecular modelling, spectroscopic 
techniques and enzymatic drug design was comprehensively reviewed and this also describes an 
overview of computational methods for this study7, 8. 
2.2 Theoretical Models 
The 3D structure of macro-molecules especially proteins can be predicted through comparative 
modelling since not all proteins readily form crystal structures suitable for X-ray analysis and 
their determination from Nuclear Magnetic Resonance (NMR) is time consuming7, 9.  
Computational chemistry involves diverse theoretical fields ranging from quantum mechanics 
(QM), molecular mechanics (MM), dynamics (MD), conformational analysis and energy 
minimizations.  All these are used to determine the chemical behaviour of molecular systems8, 10. 
2.2.1 Quantum Mechanics 
Quantum Mechanics (QM) is based on electronic structure theories meant to solve the Erwin 
Schrödinger equation (1926) usually expressed in terms of wave functions11, 12, and is used to 
understand the properties of molecules by studying the electronics of the compound13.  This 
theory is more accurate but costly considering the computational time and resources, hence more 
practical for smaller systems7, 14, 15.  There are several families of QM methods available to 
researchers.  
2.2.1.1 Semi-empirical Methods  
Currently, these methods are basically utilized for larger systems such as proteins and 
biomolecules.  Semi-empirical methods are based on quantum mechanics (QM), but due to quote 
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severe approximations only the valence electrons are considered.  It can be applied to large 
molecular systems in acceptable time frames7, 8, 16, 17.  Semi-empirical methods are often used for 
modelling large molecules such as proteins and the common theoretical methods are PM6, AM1, 
PM3, ZINDO and INDO8, 13, 18, 19.  The different theoretical approximations are designed for 
specific series of compounds; parameterization involves approximation utilizing data from 
experimental or high level ab initio calculation results20.  Researchers should therefore verify the 
suitability of the chosen method for the specific chemical system they want to study.   
2.2.1.2 Ab initio Methods 
Ab initio methods remain the most widely used electronic structure method adopted by both 
theoretical and computational chemists, despite its demanding requirements in terms of time and 
resources13, 21, 22.  These methods are centred on the laws of QM derived from theoretical 
principles21.  Examples for different levels of theory are Moller-Plesset (MPn) which includes 
electron correlation, Hartree-Fock (HF) and Configuration Interaction (CI).  QM ab initio 
methods approach the absolute experimental value as the level of theory is improved and the 
basis set increased20. 
2.2.1.3 Density Function Theory Methods (DFT) 
Kohn, Hohenberg and Sham proposed an alternative method that uses density functional models 
in the design of a more effective electronic structural method and this compute energies using 
electron density instead of the wave function23, 24.  DFT methods are faster than MP methods and 
produce similar quality of results25.  DFT is an extension of Hartree-Fock (HF) theory and Time-
Dependent DFT is an extension of DFT, and is broadly used to simulate various properties of 
both organic and inorganic compounds26.  
The hybrid model Becke3LYP by Becke27 and Lee et al28., is the most popularly used DFT29, 30 
functional especially for organic compounds.  Although, poor exchange-correlations interactions 
and low standard in estimating barrier heights have been noted31, 32.  B3LYP have been shown to 
be in agreement with high level ab initio results and give relatively good geometrics of 
molecular, organic and organometallic compounds33-36.  Hence, Becke, Lee, Yang and Parr’s 
(Becke3LYP) DFT with 6-31G(d)37, 38 basis set was used for certain parts of the system studied 
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herein.  The choice of the basis set is based on its sufficiency for the geometry optimization for 
the chosen systems.  
2.2.2 Molecular Mechanics (MM)  
This method is usually referred to as a non-quantum mechanical method since it does not make 
use of quantum mechanics instead uses the law of classical physics to describe and understand 
the behavioural pattern of atoms and molecules from a single geometry11, 39. 
Molecular mechanics can be used to model large systems such as proteins and biological 
molecules, and are characterized by force fields with fixed empirical parameters that gives it an 
edge over quantum mechanics in terms of the required computational resources and time40.  
Popular force-fields includes; Merk Molecular Force Field (MMFF)41, AMBER42 and Universal 
Force Field (UFF)43.  It is important to realise that these force fields were designed for families 
of compounds and researchers should verify the suitability of the force field for the proposed 
system under investigation.  In our case, AMBER42 force field was used which implements a 
simple harmonic model that includes torsions, bond stretch and angle bends, and also standard 
functions for Van der Waal and electrostatic interactions40, 44, 45.  Although, Gaussian package 
automatically assigns the atom types for UFF calculations, AMBER calculations require all atom 
types to be clearly defined within the molecule specification section. 
Although MM methods are less expensive, it does not explicitly calculate the electronic effect of 
chemical systems13, 39, but rather uses a very crude approximation.  One can therefore not study 
bond formation/breaking reactions with MM methods.  
In order to increase the accuracy of this method, there has been a recent increase in the 
application of combined/hybrid QM and MM methods to predict drug resistance and metabolism 
and also in the design of drugs and catalyst7, 46, 47. 
In this study, geometry optimization will be carried out using a combined QM and MM methods 
(a two-layered ONIOM48-50 approach), in investigating the binding free interaction energies of 
the HIV-1 PR inhibitors against subtype B and C-SA.  
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2.3 ONIOM Hybrid Method (QM:MM) 
Our own N-layered Integrated molecular Orbital and Molecular mechanics (ONIOM) hybrid 
(QM:MM) method was first developed by Morokuma et al48, 51, 52, and will be used in this study.  
ONIOM first appeared in Gaussian 98 and has since undergone several substantial improvements 
in Gaussian 0353.  ONIOM can be used to perform optimizations, calculate energies, predict 
electric and magnetic effects and also vibrational frequency, which makes it applicable to a large 
molecular systems48, 54. 
ONIOM model is applied to large systems and are treated at diverse level of accuracy by 
defining two or three regions within the structure known as layers54.  The high layer constitutes 
the smallest part of the region usually treated with the most accurate method (QM or DFT), and 
it is referred to as the Model System, bond formation and breaking occur in this site52, 55  
A middle region is applied in the case of a three-layer ONIOM model and it comprises a much 
larger part of the whole system than the high layer.  This is usually treated with an intermediate 
accurate model between the high and low level methods (lower level QM/DFT or semi-
empirical).  The middle layer is also referred to as the Intermediate Model System, while the 
whole molecule is also called the Real System51, 56. 
The low layer comprises the rest of the system/molecule and it is usually treated with an 
inexpensive method such as a MM method54.  In our ONIOM hybrid approach, a two-layer 
model was implemented, in which the two catalytic aspartate residues as well as the HIV PR 
inhibitors was treated at a DFT theory and the rest of the system at a low level MM (AMBER) 
theory.  
Both the two and three-layer ONIOM calculations are performed in a similar manner, and are 
represented respectively as54, 56, 57;  
 𝐸𝑂𝑁𝐼𝑂𝑀 =  𝐸𝑟𝑒𝑎𝑙
𝑙𝑜𝑤 + 𝐸𝑆𝑀
ℎ𝑖𝑔ℎ − 𝐸𝑆𝑀
𝑙𝑜𝑤                                                                        𝟐   
𝐸𝑂𝑁𝐼𝑂𝑀 =  𝐸𝑟𝑒𝑎𝑙
𝑙𝑜𝑤 + 𝐸𝐼𝑀
𝑚𝑒𝑑𝑖𝑢𝑚 + 𝐸𝑆𝑀
ℎ𝑖𝑔ℎ − 𝐸𝐼𝑀
𝑙𝑜𝑤 − 𝐸𝑆𝑀
𝑚𝑒𝑑𝑖𝑢𝑚                                       𝟑 
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Figure 4. Schematic representation of two and three-layer ONIOM models54, 56, 57 
2.3.1 Calculating Binding Free Energy with ONIOM 
All the inhibitor―enzyme complexes were treated, viewed and modelled using the Gauss view 
program, which is a pre and post-processor graphical and user interface (GUI)58.  The latest 
version of the Gaussian program is the Gaussian 09 package, which started with Gaussian 70, 92, 
94, 98 and 03 versions59. 
The binding free energies of the nine FDA HIV-1 protease inhibitors were investigated towards 
both HIV-1 subtype B and C-SA PR using the Gauss view program58 and ONIOM model 
implemented in Gaussian0960 package; ONIOM(B3LYP/6-31G (d):AMBER). 
The binding free ONIOM energy can be calculated as follow61: 
∆𝐺𝑂𝑁𝐼𝑂𝑀 ≈ ∆𝐺𝑏𝑖𝑛𝑑 = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + 𝐺𝑙𝑖𝑔𝑎𝑛𝑑                            𝟓 
Where, ∆G is the total binding energy of the system, Gcomplex, Gprotein and Gligand is the energies 
obtained from the complex (enzyme and ligand), enzyme and ligand respectively.  Specific 
computational details are presented in the respective chapters.  
 
 
34 
 
References 
[1] Heitler, W., and London, F. (1927) Interaction of neutral atoms and homopolar bond to 
quantum mechanics, in Magazine for Physics 44, 455-472. 
[2] Barcellos, G. B., Pauli, I., Caceres, R. A., Timmers, M., Saraiva, L. F., Dias, R., de Azevedo, 
J., and Filgueira, W. (2008) Molecular modeling as a tool for drug discovery, Current Drug 
Targets 9, 1084-1091. 
[3] Li, Y., and Harte, W. E. (2002) A review of molecular modeling approaches to 
pharmacophore models and structure-activity relationships of ion channel modulators in CNS, 
Current Pharmaceutical Design 8, 99-110. 
[4] Hinchliffe, A. (2005) Molecular modelling for beginners, John Wiley & Sons, New Jersey. 
[5] Mukesh, B., and Rakesh, K. (2011) Molecular docking: a review, International Journal of  
Research Ayurveda Pharmacy 2, 746-1751. 
[6] Shibata, J. H. (2012) Review of molecular modeling basics, Journal of Chemical Education 
89, 1489-1490. 
[7] Honarparvar, B., Govender, T., Maguire, G. E., Soliman, M. E., and Kruger, H. G. (2013) 
Integrated approach to structure-based enzymatic drug design: molecular modeling, 
spectroscopy, and experimental bioactivity, Chemical Reviews 114, 493-537. 
[8] Schreiner, P. R. (2007) Relative energy computations with approximate density functional 
theory—a caveat!, Angewandte Chemie International Edition 46, 4217-4219. 
[9] Cavasotto, C. N., and Phatak, S. S. (2009) Homology modeling in drug discovery: current 
trends and applications, Drug Discovery Today 14, 676-683. 
[10] Thishana, S., Krishna, B., and Hendrik, G. K. (2006) A computational study of the 
mechanism of formation of the penta-cycloundecane (PCU) cage lactam., Trends and 
Perspectives in Modern Computational Science, 7, 511-514. 
[11] Atkins, P., and De Paula, J. (2006) Atkins’ physical chemistry, New York. 
[12] Schrödinger, E. (1926) An undulatory theory of the mechanics of atoms and molecules, 
Physical Review 28, 1049. 
[13] Foresman, J., and Frish, E. (1996) Exploring chemistry, Gaussian Inc., Pittsburg, USA. 
[14] Joseph-McCarthy, D. (1999) Computational approaches to structure-based ligand design, 
Pharmacology & Therapeutics 84, 179-191. 
35 
 
[15] Cramer, C. J. (2013) Essentials of computational chemistry: theories and models, John 
Wiley & Sons, New Jersey. 
[16] Lewars, E. G. (2010) Computational chemistry: introduction to the theory and applications 
of molecular and quantum mechanics, Springer Science & Business Media, Germany. 
[17] Nicolaides, C. A. (2014) Quantum chemistry and its “ages”, International Journal of 
Quantum Chemistry 114, 963-982. 
[18] Reimers, J. R. (2011) Computational methods for large systems: electronic structure 
approaches for biotechnology and nanotechnology, John Wiley & Sons, New Jersey. 
[19] Liu, X.-T., Zhao, Y., Ren, A.-M., and Feng, J.-K. (2011) A comparative study of one-and 
two-photon absorption properties of pyrene and perylene diimide derivatives, Journal of 
Molecular Modeling 17, 1413-1425. 
[20] Frisch, A., and Foresman, J. (1996) Exploring chemistry with electronic structure methods, 
Pittsburgh PA: Gaussian Inc 302. 
[21] Ghosh, S. K., and Chattaraj, P. K. (2013) Concepts and methods in modern theoretical 
chemistry: electronic structure and reactivity, CRC Press, Florida. 
[22] Leszczynski, J. (2012) Handbook of computational chemistry, Vol. 2, Springer Science & 
Business Media, Germany. 
[23] Hohenberg, P., and Kohn, W. (1964) Inhomogeneous electron gas, Physical Review 136, 
B864. 
[24] Kohn, W., and Sham, L. J. (1965) Self-consistent equations including exchange and 
correlation effects, Physical Review 140, A1133. 
[25] Görling, A. (1992) Kohn-Sham potentials and wave functions from electron densities, 
Physical Review A 46, 3753. 
[26] Tomberg, A. (2013) Gaussian 09W Tutorial, An introduction to computational chemistry 
using G09W and avogadro software, 1-36. 
[27] Becke, A. D. (1993) Density‐functional thermochemistry. III. The role of exact exchange, 
The Journal of Chemical Physics 98, 5648-5652. 
[28] Lee, C., Yang, W., and Parr, R. G. (1988) Development of the colle-salvetti correlation-
energy formula into a functional of the electron density, Physical Review B 37, 785. 
[29] Kohn, W., Becke, A. D., and Parr, R. G. (1996) Density functional theory of electronic 
structure, The Journal of Physical Chemistry 100, 12974-12980. 
36 
 
[30] Neumann, R., Nobes, R. H., and Handy, N. C. (1996) Exchange functionals and potentials, 
Molecular Physics 87, 1-36. 
[31] Zhao, Y., González-García, N., and Truhlar, D. G. (2005) Benchmark database of barrier 
heights for heavy atom transfer, nucleophilic substitution, association, and unimolecular 
reactions and its use to test theoretical methods, The Journal of Physical Chemistry A 109, 2012-
2018. 
[32] Zhao, Y., and Truhlar, D. G. (2008) Density functionals with broad applicability in 
chemistry, Accounts of Chemical Research 41, 157-167. 
[33] Kruger, H. G., Mdluli, P., Power, T. D., Raasch, T., and Singh, A. (2006) Experimental and 
computational studies of the regioselective protection of hydantoins using anhydride, Journal of 
Molecular Structure: THEOCHEM 771, 165-170. 
[34] Goldstein, E., Beno, B., and Houk, K. (1996) Density functional theory prediction of the 
relative energies and isotope effects for the concerted and stepwise mechanisms of the diels-alder 
reaction of butadiene and ethylene, Journal of the American Chemical Society 118, 6036-6043. 
[35] Osuna, S., Morera, J., Cases, M., Morokuma, K., and Sola, M. (2009) Diels−Alder reaction 
between cyclopentadiene and C60: an analysis of the performance of the ONIOM method for the 
study of chemical reactivity in fullerenes and nanotubes, The Journal of Physical Chemistry A 
113, 9721-9726. 
[36] Ansbacher, T., Srivastava, H. K., Martin, J. M., and Shurki, A. (2010) Can DFT methods 
correctly and efficiently predict the coordination number of copper (I) complexes? a case study, 
Journal of Computational Chemistry 31, 75-83. 
[37] Hariharan, P. C., and Pople, J. A. (1973) The influence of polarization functions on 
molecular orbital hydrogenation energies, Theoretica Chimica Acta 28, 213-222. 
[38] Rassolov, V. A., Pople, J. A., Ratner, M. A., and Windus, T. L. (1998) 6-31G* basis set for 
atoms K through Zn, The Journal of Chemical Physics 109, 1223-1229. 
[39] Bultinck, P., De Winter, H., Langenaeker, W., and Tollenare, J. P. (2003) Computational 
medicinal chemistry for drug discovery, CRC Press, Florida. 
[40] Rogers, D. W. (2003) Computational chemistry using the PC, John Wiley & Sons, New 
Jersey. 
[41] Halgren, T. A. (1996) Merck molecular force field. I. basis, form, scope, parameterization, 
and performance of MMFF94, Journal of Computational Chemistry 17, 490-519. 
[42] Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., 
Simmerling, C., Wang, B., and Woods, R. J. (2005) The AMBER biomolecular simulation 
programs, Journal of Computational Chemistry 26, 1668-1688. 
37 
 
[43] Rappé, A. K., Casewit, C. J., Colwell, K., Goddard Iii, W., and Skiff, W. (1992) UFF, a full 
periodic table force field for molecular mechanics and molecular dynamics simulations, Journal 
of the American Chemical Society 114, 10024-10035. 
[44] Weiner, S. J., Kollman, P. A., Case, D. A., Singh, U. C., Ghio, C., Alagona, G., Profeta, S., 
and Weiner, P. (1984) A new force field for molecular mechanical simulation of nucleic acids 
and proteins, Journal of the American Chemical Society 106, 765-784. 
[45] Sansom, C. E., and Smith, C. A. (1998) Computer applications in the biomolecular sciences. 
Part 1: molecular modelling, Biochemical Education 26, 103-110. 
[46] Verma, J., Khedkar, V. M., and Coutinho, E. C. (2010) 3D-QSAR in drug design-a review, 
Current Topics in Medicinal Chemistry 10, 95-115. 
[47] De Benedetti, P. G., and Fanelli, F. (2010) Computational quantum chemistry and adaptive 
ligand modeling in mechanistic QSAR, Drug Discovery Today 15, 859-866. 
[48] Dapprich, S., Komáromi, I., Byun, K. S., Morokuma, K., and Frisch, M. J. (1999) A new 
ONIOM implementation in Gaussian98. Part I. The calculation of energies, gradients, vibrational 
frequencies and electric field derivatives, Journal of Molecular Structure: THEOCHEM 461, 1-
21. 
[49] Humbel, S., Sieber, S., and Morokuma, K. (1996) The IMOMO method: integration of 
different levels of molecular orbital approximations for geometry optimization of large systems: 
test for n‐butane conformation and SN2 reaction: RCl+ Cl−, The Journal of Chemical Physics 
105, 1959-1967. 
[50] Svensson, M., Humbel, S., Froese, R. D., Matsubara, T., Sieber, S., and Morokuma, K. 
(1996) ONIOM: a multilayered integrated MO+MM method for geometry optimizations and 
single point energy predictions. A test for diels-alder reactions and Pt(P(t-Bu)3)
2+ H2 oxidative 
addition, The Journal of Physical Chemistry 100, 19357-19363. 
[51] Vreven, T., and Morokuma, K. (2006) Hybrid methods: ONIOM (QM:MM) and QM/MM, 
Annual Reports in Computational Chemistry 2, 35-51. 
[52] Vreven, T., Byun, K. S., Komáromi, I., Dapprich, S., Montgomery, J. A., Morokuma, K., 
and Frisch, M. J. (2006) Combining quantum mechanics methods with molecular mechanics 
methods in ONIOM, Journal of Chemical Theory and Computation 2, 815-826. 
[53] Vreven, T., Morokuma, K., Farkas, Ö., Schlegel, H. B., and Frisch, M. J. (2003) Geometry 
optimization with QM/MM, ONIOM, and other combined methods. I. Microiterations and 
constraints, Journal of Computational Chemistry 24, 760-769. 
[54] Chung, L. W., Sameera, W., Ramozzi, R., Page, A. J., Hatanaka, M., Petrova, G. P., Harris, 
T. V., Li, X., Ke, Z., and Liu, F. (2015) The ONIOM method and its applications, Chemical 
Reviews 115, 5678-5796. 
38 
 
[55] Software, N. S. f. C. C. (2012 ) ONIOM case study on the protein alpha-conotoxin G1, 
EPSRC, UK. 
[56] Keiji Morokuma, and Vreven, T. (2000) Tutorial on the ONIOM method for inorganic 
chemistry, in ACS National Meeting ACS, Washington, DC. 
[57] Lundberg, M., Sasakura, Y., Zheng, G., and Morokuma, K. (2010) Case studies of ONIOM 
(DFT:DFTB) and ONIOM (DFT:DFTB:MM) for enzymes and enzyme mimics, Journal of 
Chemical Theory and Computation 6, 1413-1427. 
[58] Dennington, R., Keith, T., and Millam, J. (2009) Semichem Inc, Shawnee Mission KS, 
GaussView, Version 5. 
[59] Frisch, M., GWT, H., and Schlegel, G. Scuseria,; MA Robb, JRC, JA Montgomery, Jr, T. 
Vreven, 4-6. 
[60] Frisch, M., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Cheeseman, J., Scalmani, G., 
Barone, V., Mennucci, B., and Petersson, G. (2009) 09, Revision D. 01, Gaussian, Inc., 
Wallingford, CT. 
[61] Poongavanam, V., Steinmann, C., and Kongsted, J. (2014) Inhibitor ranking through QM 
based chelation calculations for virtual screening of HIV-1 RNase H inhibition, PloS one 9, 
e98659. 
 
 
 
 
  
39 
 
 CHAPTER THREE 
Investigating the binding free energies of FDA approved drugs against 
subtype B and C-SA HIV PR: ONIOM approach 
 
Zainab K. Sanusi,a Thavendran Govender,a Glenn E. M. Maguire,a,b Sibusiso B Maseko,a  
Johnson Lin,c Hendrik G. Krugera* and Bahareh Honarparvara* 
aCatalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban 4001, 
South Africa. 
bSchool of Chemistry and Physics, University of KwaZulu-Natal, 4001 Durban, South Africa. 
CSchool of Life Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. 
*Corresponding authors: Honarparvar@ukzn.ac.za (Dr Bahareh Honarparvar), 
kruger@ukzn.ac.za (Prof. Hendrik G. Kruger), Telephone: + 27 31 2601845, Fax: +27 31 
2603091, Catalysis and Peptide Research Unit, School of Health Sciences, University of 
KwaZulu-Natal, Durban 4041, South Africa. 
 
Abstract  
Human immune virus subtype C is the most widely spread HIV subtype in Sub-Sahara Africa 
and South Africa.   A profound structural insight in terms of finding potential lead compounds is 
therefore necessary for drug discovery.  The focus of this study is to test an ONIOM 
computational model for the nine Food and Drugs Administration (FDA) HIV antiviral drugs 
complexed to subtype B and C-SA PR respectively.  The experimental binding energies of the 
PR inhibitors were compared to the ONIOM calculated results.  To achieve this, an integrated 
two-layered ONIOM model was used to optimize the geometrics of the FDA approved HIV-1 
PR inhibitors for subtype B.  In our hybrid ONIOM model, the HIV-1 PR inhibitors as well as 
the ASP 25/25' catalytic active residues were treated at high level quantum mechanics (QM) 
theory using B3LYP/6-31G(d), and the remaining HIV PR residues were considered using the 
AMBER force field.  The theoretical binding free energies (ΔGbind) for subtype B follow a 
similar trend to the experimental results, with one exemption.  The computational model was less 
suitable for C-SA PR.  Analysis of the results provided valuable information about the 
shortcomings of this approach. We finally conclude that the computational model can be 
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improved by adding water to the active pocket of the catalytic residues and treat the water at a 
minimum semi-empirical level of theory (PM6).  
Keywords: HIV subtype B/C-SA PR; HIV PR inhibitors; Inhibitor―enzyme interactions; Our 
Own N-layered Integrated molecular Orbital and molecular Mechanics (ONIOM); Binding free 
energies. 
1.0 Introduction 
Acquired immune deficiency syndrome (AIDs) caused by the Human immune virus (HIV) 
remains a major disease worldwide, mostly in Africa.  The illness was first discovered in the 80’s 
by Luc Montagnier1, 2 and further categorized by Gallo et al3.  The size of infected population 
and the number of HIV patients increase yearly and this has become a major health concern4.  
The human immune virus is classified into two main types (HIV-type 1 and HIV-type 2); type 1 
is further categorize into ten subtypes5-7, of which subtype C-SA is prevalent in South Africa 
(95%)5, 8-10.  The active form of the HIV-1 protease consists of C2-symmentric, identical 99-
amino acids homodimer, bonded by hydrophobic and electrostatic forces as well as hydrogen 
bonds11, 12. 
The HIV-1 aspartic protease active site is composed of Asp25-Thr26-Gly27 catalytic triads 
enclosed by an extended two glycine rich β-sheets hairpins known as flaps7, 13.  The triads are 
located at the edge of substrate binding site, and support the catalysis cleavage (especially the 
ASP) of the scissile substrate peptide10, 14, 15.  
Antiviral inhibitors were developed against HIV-1 protease as it was considered to be the most 
eminent target16, 17.  A number of HIV-1 protease antiretroviral drugs approved by the FDA, 
were developed for subtype B, which is the more common strain found in Australia, Western 
Europe and North America.  These drugs exhibit weaker activities against subtype C and A 
found in sub-Sahara Africa and India6-8.  
The single crystal X-ray structure of the South African HIV-1 protease subtype C (C-SA HIV-1 
PR)18 was resolved and a successful modelling of this enzyme based on the peptide sequence has 
also been reported by our group19-21.  Experimental binding free energies for C-SA HIV PR have 
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previously only been determined for four of the FDA approved protease inhibitors8, 22.  Recently, 
our laboratory determined the binding free energies for all nine approved HIV PR drugs against 
C-SA HIV PR23.  
It was demonstrated before 24 that experimental binding free energies (∆Gbind) represent the most 
suitable comparative index for calculated binding free energies5, 25-27.   
The inhibitory activities of a selected number of commercial inhibitors against subtype 
B/mutants and subtype A, C, and F HIV-1 PRs were investigated using molecular dynamics 
simulations7, 28.  It was suggested that the HIV-1 PR mutations can alter the energetic and 
dynamic complexation of the enzyme and this can affect the binding properties of the inhibitors7 
leading to drug resistance.  The effect of mutations ultimately leads to drug resistance in the 
HIV-1 PR causing differences in the binding affinities of the protease inhibitors28.  Our group 
also carried out a theoretical binding free energies of the FDA approved protease inhibitors 
against both subtype B and C-SA HIV PRs using molecular dynamics (MM-GBSA)5, 10.  The 
observed results show that the absolute experimental values versus theoretical values differ due 
to the available parameterization implemented in the theoretical models which is an approximate 
of experimental data29, but still largely follow a similar trend with the experimental data for 
subtype B5, 10. 
Our Own N-layered Integrated molecular Orbital and molecular Mechanics (ONIOM) method 
was developed by Morokuma30-32.  In this multi-layered approach, the active site is treated with a 
high level of theory (Density Functional Theory or Ab Initio) while the rest of the 
system/enzyme is treated at a lower level (AMBER).  This hybrid approach allows for treatment 
of large molecular systems in different research areas33-36.  Several studies have utilized the 
ONIOM model for calculating interaction energies of wild-type HIV PR-1 with selected 
commercial inhibitors37-39 .  In all cases, the catalytic aspartate residue was treated at high level 
of theory, B3LYP/6-31G(d,p) and the rest of the system was modeled  at MM level of theory.  
The binding free energies derived from the ONIOM model were compared with other binding 
energies derived by different computational approaches.  It was concluded from the results 
obtained that the choice of the protonation state of the Asp dyad has an effect on the dynamic 
behavior of the enzyme37-39.  The choice of protonation state for the catalytic HIV PR aspartates 
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(Asp 25/25') for ONIOM calculations has been studied extensively in literature20, 21, 40-42.  It can 
be concluded that the pKa of one of the catalytic aspartate increases to 5.2 15 when bound to the 
inhibitor; the corresponding value is pKa 4.5 43 when unbound44.  This implies that one of the 
two catalytic Asp groups should be protonated for binding studies, while the other Asp is 
unprotonated 24. 
In other enzymatic studies, the ONIOM approach was extensively used to calculate the binding 
free energies of ligand―protein interactions at the B3LYP/6-31G(d):MM level of theory34, 45, 46.  
Comparison of the computed ONIOM results of the high and low potent inhibitors (-111.7 -112.3 
kcal/mol) with the reported Kd experimental dissociation constants (1.1 – 29 nM) indicated that 
the two-layer ONIOM binding energies are not always supported by experimental findings35.  
The inconsistency in the calculated ONIOM energies and experimental dissociation constants 
was attributed to the selected layer for the QM region in the two-layer ONIOM calculations35.  
In this study, a QM:MM two-layer ONIOM hybrid method was adopted to investigate the 
binding affinity of the FDA approved protease drugs against subtype B and C-SA HIV-1 
protease.  For further analysis of the obtained ONIOM binding free energies, we investigated the 
thermodynamic parameters, electrostatic and hydrogen bonding interactions for these 
inhibitor―enzyme complexes. 
2.0 Materials and Methods 
The X-ray crystal structures for the nine commercial protease drugs complexed with subtype B 
HIV PR have been reported: 4YOA (DRV)47, 4L1A (LPV)48, 4EYR (RTV)49, 3WSJ (IDV)50, 
3S56 (SQV)51, 3S45 (APV)51, 2PYM (NFV)52, 4NJU (TPV)53, 3EM4 (ATV)54 (Figure 2).  C-SA 
HIV PR (PDB code: 3U71)18 is different at eight point amino acids residue mutations with 
respect to subtype B (PDB code:1HXW)55:  R41K, L19I, T12S, H69K, I93L, I15V, L89M and 
M36I8 (Figure 1).  Structural preparation of subtype C-SA HIV PR complexed with the nine 
drugs were performed as reported before5, 10, since the X-ray structures for C-SA PR complexed 
with the FDA approved drugs have not yet been recorded in the Protein Data Bank (PDB).  
Further structural analysis were performed on these complexes to evaluate the mode of 
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interactions between the ligands and the corresponding subtype B and C-SA HIV PRs using 
Ligplot56 and Accelrys (Discovery) Visualizer57 software. 
 
 
Figure 5. Homo dimeric X-ray structure of subtype C-SA protease (PDB code:3U71) 18 adopted in this 
study, showing the positions occupied by the eight amino acids polymorphism R41K, L19I, T12S, H69K, 
I93L, I15V, L89M and M36I8 located outside the active site. This structure was created using chimera58. 
Based on the reported protonation state20, 21, 40-42 of the HIV PR, a mono-protonated Asp 25/25' 
state was induced in the binding site at physiological pH 7.  The protonation state of both HIV 
enzymes adopted in this study were assigned using PROPKA59, 60 based on standard pKa values 
at pH 7.  It is notable that all the Asp, Glu, Lys, Arg amino acids with the C and N-terminal 
groups were also charged, whereas His was kept in its neutral form39.  
To ensure that the selected inhibitors maintains the same pose inside the binding site of the 
subtype C-SA as the subtype B protease, the C-SA PR were superimposed with the subtype B 
HIV PR―inhibitor crystal complexes using PyMOL61.  The PyMOL evaluates the root mean 
square (RMS), which is a helpful measure of how well the inhibitor―enzyme complexes were 
superimposed.  An optimal superimposition is recognized if the RMS is less than 2 Å62-64. 
The structures of all inhibitor―enzyme complexes were refined afterwards by removing the ions 
and crystallographic water, that are present from the protein manually from the PDB file using a 
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text editor.  Thereafter, protons were added to the required catalytic aspartate using 
GaussView65.  The active Asp25/25' residues and the inhibitors were considered at a high level 
(QM/DFT66, 67 - B3LYP68, 69/6-31G(d)70, 71) and the remaining part of the system at low layer 
(MM - AMBER72) for subsequent ONIOM32, 73 calculations.  
Superimposed structures of all the subtype C-SA HIV PR―inhibitor complexes are provided 
with the supplementary material Figure S1.  The ONIOM (Gaussian) input files as well as the 
optimized output files of all inhibitor―enzyme complexes are also provided in PDB format with 
the supplementary material.   
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Figure 2. The structures of HIV-1 FDA approved protease inhibitors5, 10, 74, 75 
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2.1 ONIOM Binding Free Energies  
A two-layer ONIOM31, 76, 77 approach was applied to calculate the binding free energies of the 
different PR drugs with the subtype B and C-SA HIV PR.  Preceding studies showed that the 
Becke3LYP method gives better relative energies and are in agreement with high level ab-initio 
methods45, 78, 79.  Hence, full optimization calculations were carried out on both the ligands and 
inhibitor―enzyme complexes with Gaussian09 package80, using ONIOM (B3LYP/6-
31G(d):AMBER) for the QM:MM level of theory.  A schematic illustration of the ONIOM2 
model is depicted in Figure 3.  
 
 
Figure 3. Schematic diagram of the two-layered ONIOM model (B3LYP/6-31G(d):AMBER) of subtype 
C-SA―NFV HIV PR complex. 
The total interaction energy attained from the ONIOM2 calculations81, 82 is defined as:      
 ∆𝐸𝑂𝑁𝐼𝑂𝑀 = ∆𝐸𝑚𝑜𝑑𝑒𝑙,ℎ𝑖𝑔ℎ +  ∆𝐸𝑟𝑒𝑎𝑙,𝑙𝑜𝑤 −  ∆𝐸𝑚𝑜𝑑𝑒𝑙,𝑙𝑜𝑤                                                       𝟏 
Where, ∆Emodel is the energies of the model system calculated at the high and low level 
respectively and ∆Ereal presents the energy of the entire (real) system. 
The relative standard Gibbs free energies (∆G) of all reactions, were derived from the frequency 
calculations at ONIOM (B3LYP/6-31G(d):AMBER) QM:MM level of theory. Thus, the 
corresponding binding free ONIOM energies of the complex systems are calculated from: 
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 ∆𝐺𝑂𝑁𝐼𝑂𝑀 ≈ ∆𝐺𝑏𝑖𝑛𝑑 = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥  – 𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + 𝐺𝑙𝑖𝑔𝑎𝑛𝑑                                                        𝟐  
The thermodynamics quantities (enthalpy and entropy) changes were also obtained from the 
ONIOM calculation within the enzyme system for C-SA HIV PR.  The entropy (∆S) of all the 
reactions is estimated by a thermodynamic equation83. 
 ∆𝑆𝑡𝑜𝑡𝑎𝑙 = ∆𝑆𝑠𝑢𝑟𝑟𝑜𝑢𝑛𝑑𝑖𝑛𝑔𝑠 + ∆𝑆𝑠𝑦𝑠𝑡𝑒𝑚                                                                        𝟑  
∆𝑆𝑡𝑜𝑡𝑎𝑙 = ∆𝑆𝑡𝑟𝑎𝑛𝑠𝑙𝑎𝑡𝑖𝑜𝑛𝑎𝑙 + ∆𝑆𝑣𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛𝑎𝑙 + ∆𝑆𝑟𝑜𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙                                      𝟒 
3.0 Results and Discussion 
The RMS values of the superimposed inhibitor―enzyme complexes observed were in the range 
of 0.5-0.8 Å for all the 18 systems set up for this study (Figure 4), which shows a reasonably 
good superimposed prediction62-64.  Visual inspection was also performed to compare the initial 
inhibitor―enzyme complex conformation before and after optimization.  In each optimization 
process, it was observed that the selected inhibitors remained inside the active pocket of the 
individual subtype B and C-SA HIV PRs as the starting X-ray structures.  
 
Figure 4. Super-imposed inhibitor―enzyme complex of subtype B―NFV (blue) with C-SA PR (brown). 
This structure was created using PyMOL61 
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The ONIOM binding free energies for subtype B and C-SA HIV PRs with the various FDA 
approved drugs are reported in Table 1.  The experimental Gibbs energies for the 
aforementioned complexes22, 25-27 were used to evaluate the accuracy of our theoretical model.  
It is evident from the compiled experimental data that the second generation protease inhibitors 
(DRV, TPV, ATV, and LPV) show better binding affinities compared to the first generation 
(APV, SQV, RTV, NFV, IDV) against subtype B protease.  However, for subtype C-SA PR the 
only second generation inhibitor that demonstrates an improved binding energy is ATV.  
Likewise, our calculated ONIOM (B3LYP/6-31G(d):AMBER) binding free energies for subtype 
B reveal better binding affinities for the second generation inhibitors.  The calculated energy for 
ATV is considerably more negative (-85.3 kcal/mol) than other inhibitors complexed to the 
enzyme and the reasons are discussed afterwards.  The rest of the theoretical binding free 
energies for subtype B follow the same trend as the experimental energies (Table 1).  
For C-SA HIV PR there are two exemptions (outliers): TPV (-78.9 kcal/mol) and NFV (-38.6 
kcal/mol), unlike for subtype B, there appears to be no clear correlation between the trend of the 
calculated binding free energies and the reported experimental energies23.  In the previous report 
for a two-layer ONIOM model, it was realized that the general trend for theoretical binding 
energies does not always correlate with experimental data35.  Despite the uncertain correlation, 
the following more general observation was made for both experimental and computed binding 
energies for C-SA PR.  ATV, APV, IDV, RTV, and DRV exhibit comparable better binding 
affinities, while SQV, LPV and NFV revealed weaker binding affinities.    
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Table 1. The binding free energies (kcal mol-1) for HIV PIs against Subtype B and C-SA obtained by 
ONIOM (B3LYP/6-31G(d):AMBER). 
Inhibitors ∆Gbind values for Subtype B 
kcal/mol 
∆Gbind values for Subtype C-SA 
kcal/mol 
First generation PIs 
 Expa Theoryb Expc Theoryb 
RTV -13.7 -62.8 -13.9 -62.9 
APV -13.2 -56.4 -13.9 -69.0 
SQV -13.0 -54.0 -13.4 -57.1 
NFV -12.8 -46.2 -13.5 -38.6 
IDV -12.4 -45.8 -14.0 -64.0 
Second generation PIs 
DRV -15.2 -65.9 -13.8 -62.8 
LPV -15.1 -65.7 -13.2 -56.5 
TPV -14.6 -63.1 -13.2 -78.9 
ATV -14.3 -85.3 -14.4 -66.9 
Note: HIV protease inhibitors are ranked in terms of their binding free energies. 
aExperimental binding Gibbs free energies taken from literature against subtype B PR5, 22, 25-27 
bCalculated binding free energies using ONIOM for subtype B and C-SA PR respectively. 
cExperimental binding Gibbs free energies taken from literature against subtype C-SA PR23. 
The ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also 
provided in PDB format with the supplementary material. 
Several factors can potentially contribute to the different results for the two enzymes adopted in 
this study.  First, there are eight point mutations in C-SA compared with subtype B HIV PR8.  
The experimental study for subtype B and the first resolved crystal structure for subtype C-SA 
protease divulge that polymorphisms at residue 36 of the C-SA HIV PR have a significant 
influence on the stability of the enzyme hinge region.  Also, the lack of the E35-R57 salt bridge 
results in reduced stability of the hinge region; the latter contributes to increased flaps 
flexibility18 and the flap movement plays a major role in the complexation event and thus the 
binding free energies84-86. 
Subsequently, an attempt was made to achieve further insight into the detailed hydrogen bond 
interactions of the inhibitor―enzyme complexes.  The hydrogen bond distances were measured 
between both catalytic aspartates in the active pocket and hydroxyl group of the selected FDA 
approved inhibitors.  All the inhibitor―enzyme interactions were plotted using Accelrys 
(Discovery) Visualizer57 before and after optimization.  
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Figure 5. Hydrogen bond distances between the hydroxyl groups of the TPV and ATV drugs with the catalytic ASP25 
and ASP25' residues of a: subtype B―TPV PR, b: subtype B―ATV PR before and after optimization using Accelrys 
(Discovery) visualizer. Detailed comparative plots for all inhibitor―enzyme complexes are provided with the 
supplementary material Figure S3. (The ONIOM (Gaussian) input files as well as the optimized output files of all 
inhibitor―enzyme complexes are also provided in PDB format with the supplementary material.) 
Comparison of the average hydrogen bond (HB) distances between active residues of subtype B 
and C-SA PR with the selected ligands, shows that in all cases, the hydroxyl group of the 
inhibitors form hydrogen bonding with Asp25/25' of HIV proteases (Figure 5). 
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The change in hydrogen bond distances between the inhibitor -OH group and Asp 25/25' were 
calculated (Figure S3, supplementary material) for all the inhibitor―enzyme complex structures 
before and after optimization.  For subtype B, the first generation inhibitors (with weaker binding 
energies) experience a slight reduction in the average hydrogen bond distance of 0.1 Å.  While, 
the second generation inhibitors (with better binding energies) revealed a larger reduction with 
an average hydrogen bond distance of 0.5 Å upon optimization of the inhibitor―enzyme 
complex.  When the optimized inhibitor -OH and Asp25/25' hydrogen bond distances for 
subtype B/TPV (3.3 Å; -63.1 kcal/mol) are compared to that of the outlier subtype B/ATV 
complex (1.7 Å; -85.3 kcal/mol).  It is clear that ATV experiences a much stronger hydrogen 
bond interaction, most likely leading to the increased theoretical binding free energy.  
In the case of the subtype C-SA PR outliers: For TPV, comparison of the hydrogen bond 
distances with ATV reveal that TPV (3.1 Å; -78.9 kcal/mol) has a stronger hydrogen bond 
interaction than ATV (4.4 Å; -66.9 kcal/mol).  This also explains the difference in calculated 
binding free energies of these two complexes.  For the other C-SA outlier: NFV, a comparison 
with SQV that has a similar experimental binding free energy, the corresponding hydrogen bond 
distance for NFV (4.4 Å; -38.6 kcal/mol) is longer than that of SQV (4.1 Å; -57.1 kcal/mol).  
This greater distance for NFV corresponds to a weaker theoretical binding free energy. 
To further probe the nature of these differences in calculated binding free energies, the 
electrostatic and hydrogen bond interactions for both subtype B and C-SA HIV-1 PRs 
complexed with the various FDA approved inhibitors were plotted using Ligplot56 and depicted 
in Figure 6 (for subtype B―ATV) and in the supplementary material (Figure S2).  The plots 
show hydrogen bonding and electrostatic interactions occurring between the inhibitors, catalytic 
aspartate and other residues in both proteases.  However, the mode of interaction differs from 
subtype B and C-SA PR, this may be due to the polymorphism occurring in C-SA HIV PR which 
causes the enzyme to be more flexible18.   
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Figure 6. Electrostatic and hydrogen bond interactions plot of HIV subtype B PR complexed with ATV and 
LPV. These plots were created after ONIOM optimization of each complex system using Ligplot56. Detailed 
plots showing the electrostatic and hydrogen bond interactions for the remaining complexes are provided with 
the supplementary material Figure S2.  (The ONIOM (Gaussian) input files as well as the optimized output files 
of all inhibitor―enzyme complexes are also provided in PDB format with the supplementary material.) 
The calculated thermochemical properties [binding free interaction energy (∆G), enthalpy (∆H) 
and entropy (∆S) contributions] of the various drugs complexes with subtype B (Table 2) and C-
SA HIV PR are provided in supplementary material (Table S1).   
The calculated binding free energies (∆G) for the various FDA approved inhibitors complexes 
with subtype B follow the same trend as the experimental data (Table 1), except for ATV, while 
the C-SA HIV PR has two outliers (TPV and NFV) as discussed earlier.  The thermochemical 
properties can be used to explain these outliers since ∆G is a function of both enthalpy (∆H) and 
entropy (∆S).  
For the subtype B outlier, ATV: the ∆H value (-104.2 kcal/mol) (Table 2) suggests a better 
binder than the rest of the drugs complexed to the enzyme.  As demonstrated before, this may 
arise from stronger hydrogen bond interactions between the ATV hydroxyl group and the 
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catalytic aspartate residue, which translates into a larger binding free energy ∆G (-85.3 
kcal/mol).  
For the two C-SA, outliers TPV and NFV (Table S1, supplementary material), it is noticeable 
that the ∆H (-129.3 kcal/mol) for TPV also suggests better binding energy than the rest of the 
drugs in complex with the enzyme.  While ∆H (-59.3 kcal/mol) for NFV indicates a weaker 
contact.  These enthalpy values are attributed to the nature of the hydrogen bond interaction 
between the inhibitor-OH group and the catalytic aspartate (Figure 5 and subsequent 
discussion).  Thus, it reflects a stronger binding free energy ∆G (-78.9 kcal/mol) for TPV and a 
weaker binding free energy ∆G (-38.6 kcal/mol) for NFV. 
Table 2. The binding free energies, enthalpies and entropy of the various FDA approved HIV PIs against 
subtype B PR. 
Inhibitors ∆Ga  
kcal mol-1 
∆H  
kcal mol-1 
∆Stotal  
cal mol-1 K-1 
∆Strans  
cal mol-1 K-1 
∆Svib  
cal mol-1 K-1 
∆Srot  
cal mol-1 K-1 
  First generation PIs   
RTV -62.8 -70.5 -25.1 -43.9 56.8 -38.1 
APV -56.4 -81.8 -85.4 -44.5 -3.3 -37.6 
SQV -54.0 -70.1 -53.3 -45.3 31.3 -39.3 
NFV -46.2 -58.5 -41.4 -44.8 41.6 -38.2 
IDV -45.8 -67.8 -71.4 -45.0 12.9 -39.3 
  Second generation PIs   
DRV -65.9 -76.8 -37.2 -43.1 42.1 -36.3 
LPV -65.7 -99.7 -113.2 -43.5 -32.5 -37.2 
TPV -63.1 -75.1 -39.9 -43.4 41.2 -37.6 
ATV -85.3 -104.2 -63.3 -43.2 16.3 -36.5 
HIV protease inhibitors (HIV PIs) are ranked in terms of their binding free energies (ΔG), the thermodynamics values for 
subtype C-SA are provided with supplementary material (Table S1). 
aCalculated binding free energies using ONIOM for subtype B PR (taken from Table 1). 
The ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also 
provided in PDB format with the supplementary material. 
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For the various FDA approved drugs, it should be noted that more negative entropies (higher 
entropy penalty) is indicative of greater restrictions of movement for the ligand in the active site, 
due to stronger non-covalent inhibitor―enzyme interactions for certain parts of the inhibitor87.  
The translational and rotational entropy contributions are in close range for both subtype B and 
C-SA HIV PRs (Table S1), it can be seen that the major entropy contribution is from the 
vibrational energy component.  LPV demonstrates a larger entropy penalty ∆Stotal (-113.2 cal/mol 
K) for the subtype B than any of the other inhibitors.  An entropy penalty is normally paid upon 
restriction of the inhibitor87 and in this case most possibly due to stabilization of the ligand side 
chains.  Hydrogen bond interactions occur for two side chain residues of LPV with amino acids 
in the active site of the enzyme (Figure 5), which explain the observed increase in entropy value 
for LPV (Table 2).  These restrictions were not observed to the same extend for the other 
inhibitors.   
The calculated binding free energies of the FDA approved drugs against subtype B in 
comparison to C-SA HIV PR, reveals that the model works better for subtype B.  The outlier 
results for subtype B and C-SA PR appears to be due to the approximations applied in our 
ONIOM model.  Movement of the inhibitors closer to the Asp25/25' residues during 
optimization, suggest that omission of water molecules in the model is an over-simplification and 
should be addressed in future studies.  
4.0 Conclusion  
In this study, the binding free energies of the nine selected HIV-1 PR inhibitors were 
investigated using a two-layered ONIOM (B3LYP/6-31G(d):AMBER) model.  The difference in 
binding affinities of the PIs with the two proteases seems to relate to the insertion and mutants 
experienced by the mutant and the extent of binding interactions between the catalytic aspartates, 
Asp25/25', and the inhibitors. 
The calculated binding free energies for subtype B HIV PR show a satisfactory trend with the 
experimental data with one exception.  For subtype C-SA HIV PR, some discrepancies occur in 
terms of the trend with the experimental data, which means that the existing model requires 
further optimization before it can be used for C-SA PR.  
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It is known that water molecules facilitate the catalytic interactions of the substrate with the Asp 
25/25' residues, therefore the level of accuracy of the two layer ONIOM model can be improved 
by adding explicit water molecules to the active site of the HIV PR and in the least treated at a 
semi-empirical level (PM6).   
The information obtained from this research is helpful to improve the computational model for 
the potential design of more potent C-SA HIV PR inhibitors.  
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Abstract 
The aspartate protease of the human immune deficiency type-1 virus (HIV-1) has become a 
crucial anti-viral target in which many useful antiretroviral inhibitors have been developed.  
However, it seems the emergence of new HIV-1 PR mutations leads to the increase in drug 
resistance, hence, the available FDA approved drugs show less activity towards the protease.  A 
mutation and insertion designated L38L↑N↑L PR was recently reported from a novel subtype C-
SA HIV-1 PR.  An integrated two-layered ONIOM (QM:MM) method was employed in this 
study to examine the binding affinities of the nine FDA approved HIV PR inhibitors against this 
mutant.  The catalytic Asp 25/25' and HIV PR inhibitors (HIV PIs) were treated at a high level 
QM theory using B3LYP/6-31G(d), while the MM level was assigned for the remaining part of 
the system using AMBER force field.  The computed results as well as experimental data in 
general revealed a reduced inhibitory activity for all the various FDA approved drugs towards 
the L38L↑N↑L PR in comparison with subtype C-SA HIV-1 PR.  This suggests that the insertion 
and mutations significantly affect the binding affinities or characteristics of the HIV PIs and/or 
parent PR. TPV (-61.2 kcal/mol) and NFV (-24.8 kcal/mol) were outliers with respect to 
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calculated binding free energies.  The same trend for the computational binding free interaction 
energies was observed for eight of the nine inhibitors (TPV gave a better energy than 
experiment) with respect to the experimental binding free energies.  The outcome of this study 
shows that ONIOM method can be used as a reliable computational approach to rationalize lead 
compounds against specific targets. The investigation carried out in this work can help to 
improve the efficiency of future HIV-1 PR antiviral drugs. 
Keywords: L38L↑N↑L PR; HIV PR inhibitors; Inhibitor―enzyme interactions; Our Own N-
layered Integrated molecular Orbital and molecular Mechanics (ONIOM); Binding free energies. 
1.0 Introduction 
The human immune deficiency virus (subtype B) protease is one of the most recognized and 
researched enzymes regarding its function and structure and these efforts have paved the way for 
the development of effective inhibitors1, 2.  HIV-1 protease is a di-symmetric aspartyl protease 
that belongs to the group of retroviruses known as lentiviruses2-5.  
The protease (PR) is normally composed of two identical 99-amino acids in each monomer, in 
which the amino and carboxyl termini combine at the β-sheet dimer interface and form a 
hydrophobic binding site with two aspartic acids (ASP25/25') at the active site6-8. 
The HIV-1 PR functions by cleaving the gag and pol viral polypeptides into building blocks for 
protein synthesis to create a mature functional HIV virus9-12.  HIV-1 protease is one of the 
principal target for HIV/AIDS drug inhibitors since the PR is essential for the development of 
viable progeny.3, 13-15. The presence of these inhibitors significantly retracts the function of the 
PR, preventing the virus from maturing in the affected individual10, 16.  The nine HIV-1 protease 
antiretroviral drugs approved by the FDA were developed for subtype B which is the more 
common strain found in Australia, Western Europe and North America.  These drugs exhibit 
weaker activities against subtype C and A found in sub-Sahara Africa and India17-19.   
The development of HIV PR resistance due to mutations causes enormous hindrance in attaining 
long-term suppression of HIV replication in patients receiving anti-retroviral drugs20.  The 
alterations in HIV PR was investigated by Otto et al21.  They argued the actual importance of the 
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observed alterations is unclear since the mutations repeatedly occur with extra mutations in the 
protease and also in the viral genome21.  Accessing the growth properties of the mutations and 
effect of the alteration in the viral genome will help in understanding the function of the protease 
gene22, 23.  Hence, improvements can only be made on the new designed drugs since much cannot 
be done on the genetic source of drug resistance24-27. 
Our group has reported inhibitor synthesis for C-SA HIV protease and also computational 
methods to rationalize observed experimental data28-35.  A computational model to calculate the 
binding free energies of HIV PR inhibitors against subtype B and C-SA PR utilizing MM/MD 
methods was developed by our group36-38.  These computational results revealed that the absolute 
experimental values for the binding free energies versus theoretical values differ due to the 
available parameterization implemented in the theoretical model, which is an approximation of 
experimental data39.  However, the calculated results follow a similar trend with the experimental 
data for subtype B36, 37.   
We have also recently investigated an ONIOM40, 41 model to calculate the binding free 
interaction energies of the nine FDA HIV-1 protease inhibitors against subtype B and C-SA 
PR;42 these were compared with the experimental binding free energies data43.  It was observed 
that the obtained theoretical data follow a satisfactory trend with the reported experimental data 
for the subtype B PR.  However, the applied model for the C-SA HIV PR revealed limitations42.  
Several other studies have utilized the ONIOM model for calculating interaction energies of 
wild-type HIV PR-1 with selected commercial inhibitors44-46.  In all cases, the catalytic aspartate 
residues were treated at a high-level theory (DFT), and the rest of the system was modeled with 
MM.  The choice of protonation state for the catalytic HIV PR aspartates (Asp 25/25') for 
ONIOM calculations have been studied extensively in literature28, 33, 47-49.  The pKa of one of the 
catalytic aspartate increases to 5.22 when bound to the inhibitor and the corresponding value is 
pKa 4.550 when unbound51.  This implies that one of the two catalytic Asp groups should be 
protonated for binding studies, while the other Asp is unprotonated30. 
Herein, we report a hybrid ONIOM model to compute the free binding energies of the nine FDA 
approved HIV-1 protease inhibitors towards a new HIV subtype C-SA PR mutant that also 
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experience two insertions.  The C-SA HIV-1 protease mutant consists of two extra amino acids, 
resulting in a C-SA PR mutant (L38L↑N↑L)52 with 101-amino acid residues in each monomer.  
The arrow (↑) before the amino acids shows that asparagine and leucine are inserted at position 
38 respectively.  In addition, the following five mutations have also occurred in the protease 
E35D, I36G, N37S, M46L and D60E52.  
This variant was found in a patient that was drug-naïve to commercially accessible HIV protease 
drugs but reacted positively to the following reverse transcriptase inhibitors (RTIs): d4t 
(stavudine), 3TC (lamivudine), and efavirenz52. 
 
Figure 6. Schematic representation of super-imposed subtype C-SA(blue) and mutant L38L↑N↑L 
PR(brown), showing the position of the mutations (E35D, I36G, N37S, M46L and D60E) in green, 
insertions (asparagine and leucine) are depicted in red, and Asp25/25' in yellow. 
2.0 Computational Methods 
Homology modelling30, 53-56 was used to generate the three-dimensional structure for L38L↑N↑L 
protease that is necessary to start the computational process, as there is no single crystal X-ray 
structure available presently.  The same computational model as our recent ONIOM paper on 
Subtype B and C-SA was utilized42.  In this multi-layered approach, the active site was treated 
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with a high level Density Functional theory57, 58 using B3LYP59, 60/6-31G(d)61, 62 basis set, while 
the rest of the protease was treated at a low MM level using AMBER63 force field.  Further 
structural analysis to estimate the mode of interactions between the ligand and L38L↑N↑L 
protease will be performed using the Accelrys (Discovery) Visualizer64 and Ligplot65 software. 
2.1 Structural Preparation of Inhibitor―Enzyme Complexes  
The structures of clinically available FDA inhibitors complexed with the HIV-1 subtype B 
protease were taken from the Protein Data Bank (PDB).  The PDB codes are as follows: 4YOA 
(DRV)66, 4L1A (LPV)67, 4EYR (RTV)27, 3WSJ (IDV)68, 3S56 (SQV)69, 3S45 (APV)69, 2PYM 
(NFV)70, 4NJU (TPV)71, 3EM4 (ATV)72 (Figure S1).   
Since the X-ray structures for L38L↑N↑L PR complexed with the FDA approved drugs have not 
yet been reported, structural preparation input structures for the nine drugs complexed to 
L38L↑N↑L PR, were performed using the same overlay method reported previously36, 37, 42.  The 
3D structures for all the inhibitor―L38L↑N↑L mutant PR complexes were generated by 
superimposing the corresponding subtype B HIV PR―inhibitor crystal complexes with the 
L38L↑N↑L PR using PyMOL73, in order for the inhibitors to maintain the same position as in the 
subtype B PR.  PyMOL evaluates the root mean square (RMS), which is a helpful measure of 
how well the inhibitor―enzyme complexes were superimposed.  An optimal superimposition is 
considered acceptable if the RMS is less than 2 Å74-76. 
The protonation state of the L38L↑N↑L PR structure was assigned using PROPKA77, 78 based on 
the PKa values at pH 7 as presented before42.  This depicts that the catalytic aspartate at the 
active binding site in both chains Asp25 and Asp25' are deprotonated and protonated 
respectively.  It is notable that the carbonyl and amino terminus as well as the Asp, Gly, Arg, Lys 
amino acids were charged, while His is kept in its neutral form. 
The structures of all inhibitor―enzyme complexes were refined afterwards by manually 
removing the ions and crystallographic water, that are present from the protein from the PDB file 
using a text editor.  Thereafter, protons were added to the required catalytic aspartate using 
GaussView79.  The catalytic Asp25/25' residues and the inhibitors that constitute the smallest 
part of the system were considered at a high level (QM/DFT57, 58 - Beck3LYP59, 60/6-31G(d)61, 62) 
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and the remaining larger part of the system at low layer (MM - AMBER63) for subsequent 
ONIOM40, 41 calculations.  Details about the preparation of the ONIOM starting structures were 
presented before42.  
All the 3D inhibitor―protease complex structures are created using PyMOL73 software and are 
provided in supplementary material Figure S2.  The ONIOM (Gaussian) input files as well as 
the optimized output files of all inhibitor―enzyme complexes are also provided with the 
supplementary material.   
2.2 The ONIOM Evaluation Method 
An ONIOM40, 80-82 computational model was used to calculate the binding free energies of the 
various PR inhibitors with the L38L↑N↑L PR.  Preceding studies showed that the DFT level 
theory at the high level is the most popular approach due to its popular balance of accuracy and 
efficiency59, 60, 83, and B3LYP method provides good energies and are in excellent agreement 
with ab initio high level results84-86.  Therefore, the geometry of the various nine FDA approved 
drugs complexed with the L38L↑N↑L PR were optimized using the two-layer ONIOM approach 
(B3LYP/6-31G(d):AMBER) QM:MM level of theory in Gaussian0987 developed version.  The 
extrapolated energy EONIOM2
88, 89 is defined as: 
∆𝐸𝑂𝑁𝐼𝑂𝑀2 = ∆𝐸𝑟𝑒𝑎𝑙,𝑙𝑜𝑤 + ∆𝐸𝑚𝑜𝑑𝑒𝑙,ℎ𝑖𝑔ℎ − ∆𝐸𝑚𝑜𝑑𝑒𝑙,𝑙𝑜𝑤                                 𝟏 
Where, ∆Ereal is the energy of the entire (real) system and ∆Emodel is the energies of the model 
system calculated at the high and low level respectively.  A schematic representation of the 
ONIOM2 model is presented in Figure 2. 
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Figure 2. Schematic diagram of the calculated two-layered ONIOM theoretical levels (B3LYP/6-
31G(d):AMBER) of  L38L↑N↑L PR complex with APV. 
The Gibbs binding free energies (∆G) for the systems was achieved from frequency calculations 
of the optimized complexed structures using the 2-layer ONIOM algorithm as discussed above.  
Thus, the change in free energies of the corresponding complex systems is expressed as:  
∆𝐺𝑂𝑁𝐼𝑂𝑀 ≈ ∆𝐺𝑏𝑖𝑛𝑑 = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐺𝑙𝑖𝑔𝑎𝑛𝑑 + 𝐺𝑝𝑟𝑜𝑡𝑒𝑖𝑛                                𝟐 
3.0 Results and Discussion 
In order to ascertain the efficiency of the FDA approved drugs against this subtype, binding free 
interaction energy calculations were performed on all the inhibitor―protease complexes with the 
ONIOM computational model.  The average RMS values of the aligned inhibitor―L38L↑N↑L 
complex is 0.7 Å, which indicates that the complexes were correctly superimposed74-76.  The 
calculated results for L38L↑N↑L PR were ranked with the experimental data43, and also with our 
previously reported computational data for C-SA HIV PR42 (Table 1). 
The experimental results of the FDA approved drugs exhibit reduced binding free energies for 
the L38L↑N↑L PR mutant compared to the subtype C-SA HIV PR.  Only APV possesses a 
reasonable binding affinity for the mutant protease in comparison to the rest of the inhibitors. 
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The trends of the calculated binding free energies for the FDA drugs towards C-SA HIV PR has 
been discussed in our previous work42.  Here, the ONIOM (B3LYP/6-31G(d):AMBER) binding 
free energies of L38L↑N↑L PR demonstrate the same general trend as the experimental Gibb’s 
free energy data but exhibit reduced theoretical binding affinities compared to subtype C-SA PR 
(Table 1).  However, there were two exemptions (outliers); TPV shows much better binding free 
interaction energy (-61.2 kcal/mol) than other drugs complexed to the mutant enzyme. Although 
NFV exhibits the weakest binding affinity in both experimental and theoretical results for 
L38L↑N↑, the computed result appears significantly smaller than the other inhibitors (Table 1).  
Table 1. The binding free energiesa (kcal/mol) for FDA HIV PIs against C-SA and L38L↑N↑L PRs 
[reported experimental results90 and calculated ONIOM (B3LYP/6-31G(d):AMBER) results]. 
Inhibitors ∆Gbind (Exp)b  
C-SA 
∆Gbind (Exp)c 
L38L↑N↑L 
∆Gbind (Calc)d  
C-SA 
∆Gbind (Calc)e 
L38L↑N↑L 
APV -13.9 -13.1 -69.0 -56.9 
RTV -13.9 -12.9 -62.9 -56.4 
IDV -14.0 -12.1 -64.0 -52.1 
LPV -13.2 -11.6 -56.5 -51.8 
SQV -13.4 -10.1 -57.1 -45.8 
DRV -13.8 -9.88 -62.8 -43.9 
ATV -14.4 -9.69 -66.9 -43.3 
TPV -13.2 -9.47 -78.9 -61.2 
NFV -13.5 -9.38 -38.6 -24.8 
aHIV PR inhibitors with respect to their binding energies. 
b,cExperimental data for wildtype C-SA HIV PR and L38L↑N↑L PR carried out by our group respectively43, 90. 
dCalculated binding energies of wild type C-SA HIV PR previously reported by our group42. 
eCalculated binding energies for L38L↑N↑L PR. 
The ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also 
provided with the supplementary material.   
As it was argued in our previous study42, the reason for these can potentially be attributed to the 
simplified computational model (the omission of water in the active site of the protease), 
rendering the model less accurate and this possibility will be interrogated further. 
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The insertions and mutations of amino acids residues is expected to change the structure of the 
mutant PR having an impact on the binding interactions between the inhibitors and the protease.  
Hence, detailed hydrogen bond interactions of the inhibitor―enzyme complexes were measured 
using Accelrys (Discovery) Visualizer64.  The change in hydrogen bond distances were measured 
between both catalytic aspartates Asp25/25' in the binding site and the hydroxyl group of the 
FDA approved inhibitors before and after optimization (Figure 3).  In all cases, the hydroxyl 
group of the inhibitors form similar hydrogen bond interactions with the Asp25/25' of 
L38L↑N↑L PR (Figure S3, supplementary material).  For the inhibitors exhibiting slightly better 
binding affinities with the L38L↑N↑L PR (APV, RTV, IDV and LPV), a large reduction in the 
average hydrogen bond distance 0.7 Å was observed after optimization.  While inhibitors with 
weaker binding affinities (SQV, DRV, and ATV) revealed a smaller reduction of the average 
hydrogen bond distance 0.1 Å.  
For the outliers; TPV and NFV, a comparison of the hydrogen bond distances (Figure 3) reveals 
that TPV (1.6 Å; -61.2 kcal/mol) has a stronger HB interaction than NFV (1.9 Å; -24.8 
kcal/mol), explaining the difference in theoretical binding free energies for these two outliers. 
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Figure 3. Hydrogen bond distances between the hydroxyl groups of TPV and NFV drugs with the catalytic ASP25 and ASP25' 
residues of a: L38L↑N↑L―TPV PR, b: L38L↑N↑L―NFV PR before and after optimization. Detailed comparative plots for all 
inhibitor―enzyme complexes are provided in supporting information Figure S3.  (The ONIOM (Gaussian) input files as well as the 
optimized output files of all inhibitor―enzyme complexes are also provided with the supplementary material.)   
 
In an attempt to further understand the binding environment within the L38L↑N↑L PR, 
electrostatic and hydrogen bond interactions were plotted for all inhibitor―enzyme complexes 
(Figure S4 in the supplementary material) with Ligplot65.  The two exemptions; TPV and NFV 
are shown in Figure 4.  The plot for TPV reveals hydrogen bond and electrostatic interactions 
between the inhibitor and other side chain residues (NH-OH, NH-NH) in the protease which 
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most likely contribute to the improved binding calculation result.  For NFV hydrogen bond 
interactions occur with the catalytic aspartates and one side chain (mainly OH-OH) resulting in 
weaker binding affinity.   
 
Figure 4. Electrostatic and hydrogen bond interactions plots of L38L↑N↑L PR complexed with TPV and 
NPV.  The plot were created after optimization of each complex system using Ligplot65.  Detailed plots 
showing the electrostatic and hydrogen bond interactions are provided in supporting information Figure 
S4.  (The ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme 
complexes are also provided with the supplementary material.)   
As previously discussed, the calculated binding free energies (∆G) for the various FDA approved 
inhibitors complex with L38L↑N↑L PR follow the same trend with the corresponding 
experimental data (Table 1), except for TPV and NFV.  The thermochemical properties can be 
used to rationalize these outliers, since ∆G is a function of both enthalpy (∆H) and entropy (∆S).  
The calculated energies of the various drugs complexed with L38L↑N↑L PR are depicted in 
Table 2.  
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The enthalpy contribution of TPV (∆H -82.3 kcal/mol) is the highest of all cases, explaining why 
this drug binds better in theory than the other inhibitors (the enthalpy contribution is far greater 
than entropy to the Gibbs free binding energies).  As argued before (see discussion around 
Figure 3), this is most likely the result of our simplified computational model, where the 
interaction between the TPV hydroxyl group and the Asp25/25' residues are over emphasized.  
On the other hand, NFV reveals a much reduced enthalpy contribution ∆H = -42.1 kcal/mol in 
comparison to the other inhibitor―enzyme complexes, explaining the weak calculated binding 
free interaction energy (∆G -24.8 kcal/mol).   
As for the entropy results (∆S) of the various drug-complexes, it should be noted that a more 
negative entropy indicates greater restrictions of movement for the ligand in the active site, due 
to steric restrictions as well as stronger non-covalent inhibitor-enzyme interactions for certain 
parts of the inhibitor91.  Such cases result in higher entropy penalties.  The translational and 
rotational entropy contributions are in a close approximate range (-40 cal/mol K and -30 cal/mol 
K respectively) for all the inhibitors and only vary in the residual vibrational entropy ∆Svib 
(Table 2). 
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Table 2. The binding free energies, enthalpies and entropy of the various FDA approved HIV PIs against 
L38L↑N↑L PR. 
Inhibitors ∆Ga  
kcal mol-1 
∆H  
kcal mol-1 
∆Stotal  
cal mol-1 K-1 
∆Strans 
cal mol-1 K-1 
∆Svib 
cal mol-1 K-1 
∆Srot  
cal mol-1 K-1 
APV -56.9 -80.6 -79.4 -44.5 2.8 -37.7 
RTV -56.4 -80.5 -80.7 -45.5 4.7 -39.9 
IDV -52.1 -80.6 -95.7 -45.0 -11.3 -39.4 
LPV -51.8 -79.9 -94.1 -45.0 -10.1 -39.0 
SQV -45.8 -72.5 -89.4 -44.8 -5.2 -39.4 
DRV -43.9 -68.8 -83.4 -44.5 0.5 -39.4 
ATV -43.3 -72.0 -94.1 -44.8 -11.1 -38.2 
TPV -61.2 -82.3 -70.7 -45.0 13.6 -39.3 
NFV -24.8 -42.1 -57.9 -44.8 25.3 -38.4 
HIV protease inhibitors (HIV PIs) are ranked in terms of their binding free energies (ΔG). 
aCalculated binding free energies using ONIOM for L38L↑N↑L PR from Table 1. 
The ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also 
provided with the supplementary material.   
The level of consistency attained by our theoretical method with the experimental data (Table 1) 
in this study suggests the computational model can be used to rationalize the different 
drugs―mutant PR binding interactions.  However, the movement of the inhibitors closer to the 
Asp25/25' residues during optimization, imply that omission of water molecules in the model is 
an over-simplification42 and should be addressed in future studies to further improve the 
computational model. 
4.0 Conclusion  
This study involves the testing of a computational two-layered ONIOM computational model 
(QM:MM) to calculate the binding free energies of the nine FDA approved HIV-1 PIs.  The 
calculated binding free energies for L38L↑N↑L HIV PR show a satisfactory trend with the 
experimental data with two exceptions.  Two outliers were observed, and analysis of hydrogen 
bond interactions and enthalpy contributions explained the observed anomalies.  It was 
concluded that our ONIOM (B3LYP/6-31G(d):AMBER) model can be further improved by the 
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addition of water in the active pocket of the protease.  Explicit water molecules should at least be 
treated at a semi-empirical level (PM6).  These results will assist to systematically improve our 
computational model for the potential design of more potent HIV protease inhibitors. 
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 CHAPTER FIVE 
 CONCLUSION 
A geometry optimization was performed on the nine FDA approved HIV PR inhibitors using 
density functional theory [B3LYP/6-31G(d)] for the QM level of theory and Amber force field 
for the MM level.  A comparative analysis in ranking the potency of the FDA approved drugs in 
terms of binding affinities against subtype B, C-SA HIV PR was demonstrated in chapter three 
of this thesis.  It was observed that the calculated binding free interaction energies for the FDA 
HIV PR drugs complexed with the subtype B PR followed a reasonably trend with respect to the 
experimental binding free energy results. Some discrepancies occur in the calculated binding free 
energies of the FDA HIV PR inhibitors complexed with the C-SA HIV PR with respect to the 
experimental binding free energies.  A rational explanation for the observed discrepancies was 
provided, suggesting that our computational model was over simplified.  We finally concluded 
that the computational model can be improved by the addition of water to the active pocket of 
the catalytic residues and to treat the water at a minimum semi-empirical level of theory (PM6).  
A comparative analysis in ranking the potency of the FDA approved drugs in terms of binding 
affinities against the L38L↑N↑L mutant was also demonstrated in chapter four of this thesis.  It 
was discovered that the calculated binding free interaction energies for the FDA HIV PR drugs 
complexed with the L38L↑N↑L PR followed a satisfactory trend with respect to the experimental 
binding free energy results.  A rational explanation for the observed discrepancies was provided, 
again suggesting that our computational model was over simplified.   The outcome of this study 
revealed that ONIOM method can be used as a reliable computational approach to rationalize 
lead compounds against specific targets. The investigation carried out in this work can help to 
improve the efficiency of future HIV-1 PR antiviral drugs. 
Altogether, the calculated binding free interaction energies are in reasonable agreement for both 
subtype B and L38L↑N↑L HIV PR with the reported experimental data, while some 
discrepancies occur mainly with the subtype C-SA HIV PR.  An important conclusion can be 
drawn that the ONIOM model can potentially be used to compute the binding free energies of 
available inhibitors and new PR inhibitors against the corresponding HIV enzymes. 
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The catalytic Asp25 and Asp25' residues with the selected HIV inhibitors were considered at a 
high level QM; DFT theory.  In future, water will be added to the active site and treated at a 
semi-empirical middle layer, also the catalytic triads Asp25-Thr26-Gly27 will be considered at a 
high level since they also play an important catalytic role in the enzyme.  The results will then be 
compare to our previous study; also, the basis set used for the high level will also be modified to 
improve the efficiency of the computational model.  This approach will assist in 
modifying/improving our model, to obtain better insight of the interaction of the inhibitors with 
the other catalytic residues. 
Hence, information gathered in this study will facilitate the design of future potent HIV 
antiretroviral drugs by optimizing the interactions with the catalytic residues and or other 
residues of the HIV enzyme. 
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 APPENDIX A 
Supplementary Material for Chapter Three 
Investigation of the binding free interaction energies of FDA approved HIV-1 
PR Inhibitors against Subtype B and C-SA HIV PR: ONIOM Approach 
 
ZKS, TG, GEM, SBM, JL, HG* and BH* 
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Figure S7. 3D Schematic representation of C-SA HIV PR complexed with a: APV, b: ATV, c: DRV, d: 
IDV, e: LPV, f: NFV, g: RTV, h: SQV, and i: TPV PIs. (The ONIOM (Gaussian) input files as well as 
the optimized output files of all inhibitor―enzyme complexes are also provided in PDB format with the 
supplementary material.) 
i 
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 Detailed plots showing the electrostatic interactions and hydrogen bonding of subtype B and C-
SA HIV PR respectively with the selected FDA approved HIV PIs. 
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Figure S8. Electrostatic and hydrogen bon interactions plots of subtype B and C-SA HIV PR respectively with the 
various FDA approved HIV PIs. (The ONIOM (Gaussian) input files as well as the optimized output files of all 
inhibitor―enzyme complexes are also provided in PDB format with the supplementary material.) 
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Figure S9. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved ATV drug with the catalytic 
ASP25 and ASP25' residues of a1: subtype B HIV PR, a2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
 
The Figure below illustrates before and after geometry optimization was performed on all the 18 
enzyme―inhibitor complexes in determining the hydrogen bond (HB) distance between the 
catalytic Asp 25/25' and hydroxyl group of the selected FDA approved inhibitors. 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved DRV drug with the 
catalytic ASP25 and ASP25' residues of b1: subtype B HIV PR, b2: subtype C-SA PR before and after optimization.  (The 
ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in 
PDB format with the supplementary material.) 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
       
 
 
 
  
97 
 
Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved IDV drug with the catalytic 
ASP25 and ASP25' residues of c1: subtype B HIV PR, c2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved LPV drug with the catalytic 
ASP25 and ASP25' residues of d1: subtype B HIV PR, d2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved NFV drug with the catalytic 
ASP25 and ASP25' residues of e1: subtype B HIV PR, e2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved RTV drug with the catalytic 
ASP25 and ASP25' residues of f1: subtype B HIV PR, f2: subtype C-SA PR before and after optimization.   (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved SQV drug with the catalytic 
ASP25 and ASP25' residues of g1: subtype B HIV PR, g2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB 
format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved TPV drug with the 
catalytic ASP25 and ASP25' residues of h1: subtype B HIV PR, h2: subtype C-SA PR before and after optimization.  (The 
ONIOM (Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in 
PDB format with the supplementary material.) 
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Figure S3. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved ATV drug with the catalytic 
ASP25 and ASP25' residues of i1: subtype B HIV PR, i2: subtype C-SA PR before and after optimization.  (The ONIOM 
(Gaussian) input files as well as the optimized output files of all inhibitor―enzyme complexes are also provided in PDB format 
with the supplementary material.) 
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Table S3. The Free energies, Entropy and Enthalpies contributions of FDA approved HIV PIs against subtype 
C-SA PR. 
Inhibitors ∆Ga  
kcal mol-1 
∆H  
kcal mol-1 
∆Stotal  
cal mol-1 K-1 
∆Strans  
cal mol-1 K-1 
∆Svib  
cal mol-1 K-1 
∆Srot  
cal mol-1 K-1 
  First generation PIs   
RTV -62.9 -82.6 -67.0 -44.5 15.4 -37.9 
APV -69.0 -102.3 -110.9 -43.5 -31.7 -35.7 
SQV -57.1 -79.3 -74.0 -44.3 7.6 -37.4 
NFV -38.6 -59.4 -69.7 -43.8 10.6 -36.4 
IDV -64.0 -91.3 -91.6 -45.0 -7.2 -39.4 
  Second generation PIs    
ATV -66.9 -84.8 -60.3 -43.8 19.9 -36.2 
DRV -62.8 -87.5 -82.4 -43.3 -3.0 -36.1 
LPV -56.5 -81.3 -83.1 -44.1 -2.1 -36.9 
TPV -78.9 -129.3 -169.2 -44.0 -88.0 -37.3 
HIV protease inhibitors (HIV PIs) are ranked in terms of their binding free interaction energies (ΔG). 
aCalculated binding free interaction energies using ONIOM for subtype C-SA PR (taken from Table 1) 
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 APPENDIX B 
Supplementary Material for Chapter Four 
Exploring the Binding Free energies of FDA approved PR Inhibitors against 
novel C-SA HIV-1 PR mutant L38L↑N↑L PR: ONIOM method 
 
ZKS, TG, GEM, SBM, JL, HG* and BH* 
 
The figure below shows the 3D structures of the novel C-SA HIV PR mutants designated 
L38L↑N↑L PR―inhibitor complexes. 
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Figure S10. 3D Schematic representation of L38L↑N↑L PR complexed with a: APV, b: ATV, c: DRV, d: IDV, e: 
LPV, f: SQV, g: RTV, h: NFV, and i: TPV PIs. 
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Figure S11. The structures of the FDA approved HIV PR inhibitors. 
108 
 
Detailed plots showing the electrostatic interactions and hydrogen bonding of L38L↑N↑L PR 
with the selected FDA approved HIV PIs. 
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Figure S3. Electrostatic and hydrogen bond interactions plots of L38L↑N↑L PR with the selected FDA approved HIV PIs. 
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Figure S4. Hydrogen bond distances between the OH group of the FDA approved drugs a: APV, b: ATV with the catalytic 
Asp 25/25’ residues of L38L↑N↑L before and after optimization.  
The Figure below illustrates before and after geometry optimization was performed on all 
L38L↑N↑L PR―inhibitor complexes in determining the hydrogen bond (HB) distance between 
the catalytic Asp 25/25' and hydroxyl group of the selected FDA approved inhibitors. 
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Figure S4. Hydrogen bond distances between the OH group of the FDA approved drugs c: DRV, d: IDV with the catalytic Asp 
25/25’ residues of L38L↑N↑L before and after optimization. 
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Figure S4. Hydrogen bond distances between the OH group of the FDA approved drugs e: LPV, f: SQV with the catalytic Asp 
25/25’ residues of L38L↑N↑L before and after optimization.  
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Figure S4. Hydrogen bond distances between the hydroxyl groups of the selected FDA approved drugs g: RTV, h: NFV, with 
the catalytic Asp 25 and Asp25' residues of L38L↑N↑L PR before and after optimization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
